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Abstract for Thesis Portfolio 
Insulin misuse in type 1 diabetes is frequently reported in the literature and is 
associated with poor health outcomes. The reasons for this behaviour have been 
under-researched; however, weight control and disordered eating are frequent 
themes.  Little research has explored this in type 1 diabetes specifically, and most 
have focused on the experiences of females and adolescents. The research aims of 
this project are: 1. To critically review, assess, and evaluate whether insulin misuse 
for the purposes of weight loss or control is reported by males with type 1 diabetes 
and to what degree; 2. To explore the relationships between insulin misuse and 
gender, eating disorder psychopathology, body shape satisfaction and diabetes-
related distress.  
A systematic review was carried out to investigate insulin misuse for weight 
purposes amongst males with type 1 diabetes, and the prevalence of this. The 
evidence suggested that males report misusing insulin for weight purposes when 
assessed using self-report measures, but do not report this during clinical interviews. 
Prevalence rates could not be established from the studies included in the review due 
to the heterogeneity of the measures used.  
An empirical study was carried out using a cross-sectional self-report design, 
and 219 completed datasets were included in the analysis (78% female). Insulin 
misuse was common, with women significantly more likely to misuse insulin than 
men. Those who had a current or historical diagnosis of an eating disorder were 
more likely to misuse insulin for weight loss or control than those with no history of 
an eating disorder. People who reported insulin misuse had significantly higher 
levels of disordered eating behaviours, more negative feelings about body shape and 
 8 
greater degrees of diabetes-related distress. Diabetes-related distress was the only 
predictor of insulin misuse. 
Theoretical and clinical implications are identified and recommendations for 
further research are discussed. 
 
 
 
 9 
Acknowledgements 
I would firstly like to thank the diabetes community for being the most 
supportive and helpful group of people to work with. You have all been an 
inspiration to me and have taught me so much about the realities of living with 
diabetes. I am so grateful to each and every person who participated in this study, but 
also to those who retweeted and shared the link to my study to such a wide audience.  
Thank you to my research supervisors, Dr Sian Coker and Dr Bonnie Teague, 
for introducing me to this topic and supporting me through the long process of 
getting from an idea to a thesis. Your guidance and expertise have shaped my future 
career. Thanks to my fellow trainees, whose empathy, humour and support made this 
journey so much easier. Thank you to my friends and family, particularly my mum, 
for your patience and willingness to listen to me offloading, and for being 
understanding of the times when I dropped off the radar! And finally, thank you to 
my amazing husband, without whom I could never have made it through this 
process.  
   
 10 
Introduction to Thesis Portfolio 
This thesis portfolio consists of two main papers: a systematic review and an 
empirical paper, exploring insulin misuse in people with type 1 diabetes. A bridging 
chapter links these two papers. Extended Methods and Results chapter are included 
to provide further information, and a Discussion and Critical Evaluation chapter 
considers the wider implications of both the systematic review and the empirical 
paper. 
Diabetes is a serious illness that places a significant burden on the NHS. It 
currently affects about 4.5 million people in the UK. It is currently estimated that 
about £10 billion is spent by the NHS on diabetes per year (Diabetes UK, 2016). 
Poor management of diabetes can cause significant physical health concerns, 
including: cardiovascular disease (Emerging Risk Factors Collaboration, 2010); eye 
disease (Liew, Michaelides & Bunce, 2014); amputations (Khanolkar, Bain & 
Stephens, 2008); and nerve damage (Boulton, 2005).  
Diabetes may also have a considerable impact on mental health, particularly 
the impact of coming to terms with a diagnosis, dealing with complex medication 
regimes, and potential complications and side effects. A large-scale study by 
Mommersteeg, Herr, Pouwer, Holt and Loerbroks (2013) suggested that people with 
diabetes are twice as likely to suffer a depressive episode compared with a non-
diabetic population, and these episodes may be longer-lasting and reoccur more 
frequently (Mezuk, Eaton, Albrecht & Golden, 2008). 
Broadly speaking, diabetes consists of two types: Type 1 and Type 2 diabetes 
mellitus. Usually, the pancreas synthesises insulin, a hormone that converts glucose 
from food into energy for the body. In type 1 diabetes, the pancreas does not produce 
insulin. This leads to a build-up of glucose in the blood, which is eventually excreted 
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in urine (Atkinson, Eisenbarth & Michels, 2014). Once diagnosed, a person with 
type 1 diabetes must administer artificial insulin to regulate their blood glucose 
levels (National Institute for Health and Care Excellence [NICE], 2015). This is a 
complex procedure, requiring regular monitoring of blood glucose levels and 
following a structured insulin-therapy routine (NICE, 2015). Type 1 diabetes is 
generally diagnosed in childhood and accounts for approximately 10% of diabetes 
diagnoses (Atkinson et al., 2014).  
In Type 2 diabetes, the pancreas does not produce enough insulin (NICE, 
2017). It can generally be managed through medication and careful control of diet; 
however, insulin treatment may be necessary as the disease progresses (NICE, 
2017). Type 2 diabetes is typically diagnosed in adulthood, and it accounts for up to 
90% of diabetes diagnoses (NICE, 2017). 
For people with type 1 diabetes, three main insulin management approaches 
are used: a twice-daily regimen, multiple daily injection therapy (also known as a 
basal-bolus regimen) or an insulin pump (NICE, 2015). For those adhering to a 
twice-daily regimen, a strict routine is required. Although the lower number of daily 
injections may be preferable, this regimen does not allow for much flexibility. On 
the other hand, a basal-bolus regimen allows for greater flexibility, but also requires 
constant monitoring of blood sugar levels and an increased number of daily 
injections. Insulin pumps provide insulin throughout the day but are not available to 
everyone with type 1 diabetes under the NHS, with NICE guidelines suggesting that 
they should be provided by the NHS in the event that blood glucose levels cannot be 
managed through other means (NICE, 2015).  
Research suggests that people with type 1 diabetes do not always adhere 
correctly to their prescribed insulin regime (e.g. Polonsky et al., 1994; Schober et al., 
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2011). The reasons for this have not been well-explored to date, although evidence 
suggests that it may often be related to weight loss or control behaviours (de Paoli & 
Rogers, 2017), or to the burden of type 1 diabetes on a lifestyle (Ames, 2017; Peyrot, 
Rubin, Kruger & Travis, 2010). Given that serious health complications, including 
comorbidities and fatalities, can arise from incorrect management of type 1 diabetes, 
gaining an understanding of this behaviour is important for health care professionals. 
Much of the research that has been conducted has been focused on women, and there 
is a paucity of research that explores men’s reasons for poor insulin adherence.  
The incidence of eating disorders (defined as the number of new cases 
diagnosed in a period of time) has increased for both males and females in the 
United Kingdom between 2000 and 2009, from an age-standardised incidence of 
32.3 per 100,000 people in 2000 to 37.2 per 100,000 in 2009 (p < .00001; Micali, 
Hagberg, Petersen & Treasure, 2013). For males specifically, the incidence estimates 
increased from 5.6 per 100,000 to 7.1 per 100,000 in that time period (Micali et al., 
2013). However, the incidence rates of Anorexia Nervosa (AN) and Bulimia 
Nervosa (BN) remained quite stable for men, but the incidence of Eating Disorder 
Not Otherwise Specified (EDNOS) increased by 24% (from 3.1 to 4.2 per 100,000). 
A similar finding was seen for females, with rates of AN and BN remaining steady 
overall, but rates of EDNOS increased significantly from 17.7 per 100,000 in 2000 
to 28.4 per 100,000 in 2009. By 2009, EDNOS was the most commonly diagnosed 
eating disorder for both males and females (Micali et al., 2013).  
Within people with type 1 diabetes, EDNOS has recently been found to be 
the most common diagnosis of an eating disorder, with 0.8% of females and 0.25% 
of males with type 1 diabetes diagnosed with EDNOS in a large-scale study 
(Scheuing et al., 2014). Of note, this study only explored previously diagnosed 
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eating disorders that reached a clinical threshold and may have failed to account for 
sub-threshold or undiagnosed eating disorders. Nonetheless, this appears to be an 
increase in the reported proportion of cases at a given time (i.e. prevalence rates) 
reported in earlier studies, such as Bryden et al. (1999) who reported a prevalence 
rate of 0.025% for males with type 1 diabetes and comorbid EDNOS, and Fairburn 
et al. (1991) who found no presence of eating disorders in men with type 1 diabetes.  
Taken together, these findings suggest that rates of eating disorders are 
increasing for both men and women, and that there is an increase in eating disorder 
psychopathology for men and women with type 1 diabetes. However, the available 
research has tended to focus on the experience of females and adolescents, with 
limited attention being given to insulin misuse as a method of weight loss or control, 
and little research exists that explores these behaviours in adults and men with type 1 
diabetes. 
The systematic review aims to address the gap in the research with regard to 
the experience of men and seeks to explore the prevalence of insulin misuse in men 
with type 1 diabetes for the purposes of weight control or loss. The empirical paper 
takes a broader approach in investigating the reasons for insulin misuse in adult men 
and women with type 1 diabetes, including exploring links to eating disorder 
psychopathology and diabetes-related distress, and a specific measure of insulin 
adherence is included to capture the nuances of the behaviour.  
A note on language 
The term “insulin misuse” is commonly used in the literature to describe the 
practice of not taking insulin as prescribed. This can include omitting doses or taking 
an incorrect dose (either too much or too little). Many people in the diabetes 
community find this language problematic as they feel it is blaming. This was 
 14 
highlighted by lay members (Experts by Experience) of the diabetes community at 
the beginning of participant recruitment for the empirical paper. An amendment was 
submitted to the Ethics committee to adjust the language in the survey to remove the 
term “misuse”. However, given the requirement of concise language in published 
research, particularly when writing for journals with a limited word count, the 
decision was made to use the term “insulin misuse” throughout the Thesis portfolio, 
as no suitable concise alternative was found.  
Glossary of terms 
Diabetic Ketoacidosis. This is a serious medical condition where a lack of 
insulin means that glucose cannot be broken down for energy, and the body begins to 
target other body tissues as energy sources. Chemicals called “ketones” start to build 
up in the body which can be harmful and can ultimately lead to a coma or even death 
if not treated (Kitabchi & Wall, 1995).  
Glycaemic Control. This refers to control of blood sugar levels in a person 
with diabetes (Herman, 1999).  
HbA1c. This is a measurement that reflects an individual’s average blood 
glucose (sugar) level over the past two to three months, and it is considered the best 
way of monitoring glycaemic control (Marshall & Barth, 2000).  
Hyperglycaemia (“Hyper”). Hyperglycaemia occurs when the blood glucose 
levels becomes too high. It can be caused by a number of factors, including omitting 
or taking too little insulin, or eating more carbohydrates than suitable for the insulin 
dose taken. Physical symptoms include increased urine output, rapid weight loss and 
dehydration. If serious and untreated, it can lead to diabetic ketoacidosis (Jarrett & 
Keen, 1976).  
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Hypoglycaemia (“Hypo”). Hypoglycaemia occurs when the blood glucose 
level falls too low. This can occur when the correct dose of insulin is not taken in 
relation to the food eaten or physical activity being carried out. It causes physical 
symptoms including trembling, sweating, tiredness, feeling hungry or faint and 
trouble concentrating (Cryer, Davis & Shamoon, 2003). 
Insulin adherence. Insulin adherence generally refers to following the 
prescribed insulin regime correctly (Cramer, 2004).  
Insulin misuse. Insulin misuse is an umbrella term that covers all the ways in 
which an insulin regime may not be followed correctly (Bryden et al., 1999), 
including insulin omission, underdosing and overdosing (see below).  
Insulin omission. Insulin omission is generally understood to mean not 
taking one or more doses of insulin (Polonsky et al., 1994). 
Insulin underdosing or overdosing. This refers to taking too little 
(underdosing) or too much (overdosing) insulin at a time (Bryden et al., 1999). 
Insulin underdosing may also be referred to as ‘insulin restriction’.  
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Abstract 
Background 
Insulin misuse in type 1 diabetes is a risky behaviour frequently reported in the 
literature. The reasons for insulin misuse have been under-researched; however, 
weight control emerges as a common theme in existing studies.  There appears to be 
an association between eating disorders and insulin misuse, but little research has 
explored this in type 1 diabetes specifically. Previous research has tended to focus on 
the experience of females, resulting in males being under-represented in the 
published literature.  
Purpose 
This review aims to investigate whether males report misusing insulin for weight 
purposes, and to explore reported prevalence rates for this behaviour. 
Data Sources 
Multiple databases, including MEDLINE Complete, PsycINFO and Pubmed, were 
systematically searched.  
Study Selection 
Sixteen papers were identified that explored adherence to an insulin regimen in a 
population that included males with type 1 diabetes, where questions were also asked 
about weight loss or control behaviours.  
Data Extraction 
Data were extracted, including demographic details, study design, measures and 
results. 
Data Synthesis 
Information from the studies was tabulated and a narrative synthesis approach was 
used to qualitatively summarise the findings.  
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Limitations 
The heterogeneity of the studies, particularly the assessment of insulin misuse, 
hampered interpretation.   
Conclusions 
The evidence suggested that males report misusing insulin for weight purposes when 
assessed using self-report measures, but do not report this during clinical interviews. 
Prevalence rates could not be established from the studies included in the review due 
to the heterogeneity of the measures used. Future research should aim to address this.  
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A diagnosis of type 1 diabetes produces a requirement to adhere to a regimen of 
insulin administration. Taking insulin as prescribed is generally referred to as 
adherence. Insulin misuse is an umbrella term that can refer to either deliberately 
under-dosing, over-dosing or omitting a scheduled dose of insulin (omission) (1). 
Omission and under-dosing can lead to hyperglycaemia and rapid weight loss may 
be seen through a combination of dehydration and caloric restriction (2). Due to the 
severity of the consequences, insulin misuse by people with type 1 diabetes is an 
area of particular concern for health professionals (3).  
Limited research has been carried out into the reasons for which people may 
misuse insulin. One study found that the majority of insulin users, both males and 
females, report intentional insulin omission, and it was a common behaviour 
amongst 20% of these individuals (4). A global study found that 34.6% of 
respondents had intentionally omitted insulin at least once during the previous 
month, and men were more likely to omit insulin than women (5). Reasons for 
omission reported included interference with daily activities, pain and 
embarrassment related to injections, the perception of insulin therapy as interfering 
with one’s lifestyle, difficulty with injections and frustration with the regimented 
nature of insulin treatment (4,5). Concerns about weight amongst women were 
associated with poorer insulin adherence (6). Other reasons for insulin misuse 
reported in the literature include: forgetting (7); embarrassment (8); emotional 
distress related to diabetes, avoidance related to fear or anxiety and as an adaptive 
response to fluctuating blood sugar levels (9). 
The comorbidity of eating disorders and type 1 diabetes was first identified in 
the 1980s (10). Herpertz et al. (11) found a point prevalence for eating disorders of 
7.9% for female respondents and 2% for males with type 1 diabetes, with an average 
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lifetime prevalence of 10% across both genders. The study identified that 4.1% of 
participants reported insulin omission. Nielsen (12) reported that rates of insulin 
misuse were increased when an eating disorder co-existed with type 1 diabetes. More 
recently, NICE released guidelines stating “…be alert to the possibility of bulimia 
nervosa, anorexia nervosa and insulin dose manipulation in adults with type 1 
diabetes …” (13). 
Insulin misuse for the purposes of weight loss or control has been reported 
several times in previous research (e.g. 14), and is referenced in the Diagnostic and 
Statistical Manual of Mental Disorders 5th Edition (DSM-5) (15, p. 314). This 
practice has been referred to as “diabulimia” (16). However, research is currently 
very limited, and the area would benefit from further investigation to assess 
appropriate treatment implications, as standard treatment for eating disorders has 
been ineffective in reducing rates of insulin misuse (17).  
To date, little research has explored the rate of insulin misuse within eating 
disorder psychopathology in people with type 1 diabetes specifically, and the 
research that has been undertaken has tended to focus on females. In a recent review 
(14), 13 studies of 31 (42%) involved only female participants. No studies involved 
only male participants. Incidence rates of eating disorders in males are increasing 
(18), and recent research into men with type 1 diabetes and comorbid eating 
disorders suggests that rates may be increasing compared to earlier research (19–21). 
Eating disorders in men may have different presentations to those typically seen in 
females, including a desire for muscularity over thinness (22), so results cannot be 
generalised across genders (23).  
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Aims and Objectives 
To begin to address the gap in the literature regarding prevalence rates of 
insulin misuse for weight control or weight loss by men with type 1 diabetes, a 
systematic review was conducted. This study aims to add to the increasing empirical 
evidence regarding the misuse of insulin for weight control or loss (henceforth called 
‘weight purposes’ for brevity), in order to improve awareness of this behaviour. This 
review appears to be the first of its kind as males have been under-represented in the 
research (14).  
The review aims to address the following questions: 
• Do men report misusing insulin for weight purposes? 
• If so, what are the prevalence rates for this behaviour? 
 
Methods 
Data Sources and Searches 
The Preferred Reporting Items for Systematic Reviews and Meta-Analyses 
(PRISMA) guidelines (24) were used to shape a systematic review of literature that 
investigated insulin misuse for weight purposes in males with type 1 diabetes. A 
broad search strategy with no historical start date was implemented to maximise the 
yield of relevant papers. Databases searched included MEDLINE Complete, 
PsycINFO and PubMed in February and March 2018. The reference sections of 
relevant articles were screened for further literature that may have been missed. 
Unpublished research was considered provided the full-text paper was available. The 
search was restricted to articles available in the English language.  
The search strategy is outlined in Table 1.  
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Table 1 
Search Strategy for Systematic Review of Literature 
Operator Search Term Field    All Databases Searched 
AND insulin misuse 
OR insulin 
omission OR 
insulin 
underdos* OR 
insulin 
adherence 
Abstract MEDLINE Complete  
Academic Search Complete  
Complementary Index  
CINAHL Complete  
Journals@OVID  
ScienceDirect  
Supplemental Index  
PsycINFO  
Directory of Open Access Journals  
JSTOR Journals  
British Library EThOS  
ERIC  
SCOPUS 
Pubmed 
Proquest 
American Doctoral Dissertations 
Child Development & Adolescent 
Studies 
eJournals 
PsychArticles 
 
AND weight control 
OR weight loss 
OR weight 
manipulation 
OR weight 
Abstract 
AND type 1 diabetes 
or t1d OR 
diabetes 
mellitus OR 
juvenile 
diabetes OR 
insulin-
dependent 
diabetes 
Abstract 
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Eligibility Criteria  
Eligibility criteria for inclusion in the review included: a population with type 
1 diabetes who were prescribed an insulin regime, in which questions were asked 
regarding adherence to an insulin regime and weight loss or control behaviours. 
Studies with a mixed population that included people with type 1 and type 2 
diabetes, or both male and female participants, were included, provided that separate 
analyses of insulin misuse were conducted that clearly identified type 1 male 
participants. All quantitative designs were considered.  
Exclusion criteria included studies that exclusively studied a population with 
type 2 diabetes or gestational diabetes, due to the different pathophysiology and 
treatments compared to type 1 diabetes (4), or mixed populations in which analyses 
were not conducted separately. Studies that focused exclusively on female 
participants were also excluded. Qualitative and case studies were excluded on the 
basis of sample size, and review papers were excluded as they did not constitute new 
research. 
Study Selection 
The initial search yielded 3312 results, and 20 results identified through hand 
searching. Following duplicate removal, 949 results were screened against the 
inclusion criteria. Stage 1 involved screening the title and abstract of the paper for 
suitability based on the inclusion and exclusion criteria. Articles that clearly did not 
meet the inclusion criteria were removed (N = 912). In the event of ambiguity as to 
whether the article was appropriate, and for papers who passed Stage 1 screening, 
the full-text of the article was screened against the inclusion criteria. A further 21 
papers were removed. A second reviewer (BT) independently reviewed the full text 
of the remaining papers against the inclusion criteria, with no disagreements 
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identified. Sixteen papers were considered eligible for data extraction and included 
in this review.  
Figure 1 depicts this process in more detail.  
 
Figure 1. Study selection flowchart, based on PRISMA guidelines (24) 
Data Extraction and Quality Assessment  
Data were extracted by the first author (VM). Information extracted included 
demographic details, design, measures and results. A number of pre-existing quality 
assessment tools were considered, including the Quality Assessment Tool for 
Quantitative Studies (25). However, none of the tools were a perfect fit for this 
study, so relevant elements were extracted to create a novel Quality Assessment tool, 
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(n=279) 
* Not relevant to focus of 
review (n=157) 
* Case study, review or 
qualitative study (n=58) 
* Excluded men or combined 
genders (n=23) 
* Full text unavailable (n=3) 
Full-text articles assessed 
for eligibility 
(n = 37) 
Excluded articles (n = 21): 
 Combined genders (n=7) 
* Full text unavailable (n=7) 
* Insulin adherence not specifically 
measured or explored (n=3) 
* Weight control and insulin adherence 
considered separately (n=2) 
* Review (n=2) 
 
Studies included in 
narrative synthesis 
(n = 16) 
 26 
tailored specifically for this review. This tool was developed in discussion with SC 
and BT and subsequently piloted by another independent researcher who assessed a 
sample of papers using the tool. Two questions were found to be unhelpful in 
effectively assessing the quality of papers, so were removed and replaced with three 
new questions. See Supplementary Table 1 for full details of this tool. 
 A second rater (SC) independently rated 25% of the final studies (N = 4) that 
were randomly selected for the purposes of inter-rater reliability, using the same 
tool. One minor difference was found in ratings, which was discussed and resolved 
by amending a rating. See Supplementary Table 2 for full details of the quality 
assessment ratings.   
Data Synthesis and Analysis 
Given the heterogeneity of the studies included in this analysis, a meta-
analysis was not appropriate (26). Instead, a narrative synthesis was considered 
suitable, which is a method of qualitatively summarising each study in order to 
generate an explanation of the findings.  
Results 
Sixteen studies were included in the final review. Thirty studies were 
excluded on the basis of combining the genders in the results or for focusing 
exclusively on female participants (Figure 1). No study was identified that focused 
exclusively on male participants. Rates of insulin misuse for weight purposes 
amongst men varied significantly across the included studies, as did the measures 
used to assess this. Table 2 lists the study characteristics of the included studies. 
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Supplementary Table 1 
 
Quality Assessment Rating Scale 
 
Category 
 
Is the 
question or 
objective 
sufficiently 
described? 
Was an 
appropriate 
study design 
identified and 
used? 
Are participant 
characteristics 
described?  
Were the 
general 
reliability and 
validity of 
measures 
reported? 
How was 
insulin 
misuse 
assessed? 
Were the 
study-specific 
reliability and 
validity of 
measures 
assessed and 
reported? 
Were results 
analysed and 
reported in 
sufficient 
detail? 
Do results 
support the 
conclusions? 
Overall Scores 
Description of 
Rating 
2 = Yes 
1 = 
Partially 
0 = No 
2 = Yes  
1 = Not clearly 
identified, or 
not totally 
appropriate for 
the research 
questions 
0 = Design not 
identified or 
does not answer 
research 
question 
2 = At least two 
characteristics 
described 
1 = One 
characteristic 
described 
0 = Participant 
characteristics 
absent 
2 = Yes, both 
reported 
1 = Either 
reliability or 
validity 
reported, or 
not for all 
suitable 
measures 
0 = Neither 
reliability or 
validity 
reported 
2 = Two or 
more specific 
questions  
1 = Single 
question 
asked  
0 = Indirect 
or non-
specific 
question (e.g. 
“Have you 
done 
anything else 
to control 
your 
weight?”) 
 
2 = Yes, both 
reported 
1 = Either 
reliability or 
validity 
reported, or 
not for all 
suitable 
measures 
0 = Neither 
reliability or 
validity 
reported 
2 = Yes 
1 = Partially 
(some 
information 
missing) 
0 = No (e.g. 
reported for 
subsample 
only) 
2 = Yes, all 
conclusions are 
supported by 
data 
1 = Major 
conclusions are 
supported by 
data 
0 = Conclusions 
are not well 
supported by 
data 
14 - 16: 
Excellent 
11 - 13: Very 
Good 
8 – 10: 
Reasonable  
0 – 7: Poor 
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Supplementary Table 2 
Quality Rating of Included Studies 
Authors and Date Is the 
research 
question or 
objective 
sufficiently 
described? 
Is an 
appropria
te study 
design 
used?  
 
Are general 
reliability 
and validity 
of measures 
reported? 
Description of 
participant 
characteristics 
 
Assessment 
of insulin 
misuse 
Are study-
specific 
reliability 
and 
validity 
reported? 
Are results 
analysed 
and 
reported in 
sufficient 
detail?  
 
Do the 
results 
support the 
conclusions? 
 
Overall 
Quality Rating  
(0 – 16) 
Neumark-Sztainer, D., 
Patterson, J., Mellin, A., 
Ackard, D. M., Utter, J., 
Story, M., & Sockalosky, 
J. (2002) 
 
2 2 2 2 2 2 2 2 16 (Excellent) 
Bryden K, Neil A, 
Mayou R, Peveler R, 
Fairburn C & Dunger D 
(1999) 
 
2 2 2 2 2 0 2 2 14 (Excellent) 
d'Emden, H., Holden, L., 
McDermott, B., Harris, 
M., Gibbons, K., 
Gledhill, A., & Cotterill, 
A. (2013). 
 
2 2 2 2 2 1 1 2 14 (Excellent) 
Fairburn, C. G., Peveler, 
R. C., Davies, B., Mann, 
J. I., & Mayou, R. A. 
(1991) 
 
2 2 2 2 2 0 2 2 14 (Excellent) 
Wisting, L., Frøisland, 
D. H., Skrivarhaug, T., 
Dahl-Jørgensen, K., & 
Rø, Ø. (2013) 
 
2 2 2 2 2  
0 
2 2 14 (Excellent) 
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Supplementary Table 2 continued 
  
        
Authors and Date Is the 
research 
question or 
objective 
sufficiently 
described? 
Is an 
appropria
te study 
design 
used?  
 
Are general 
reliability 
and validity 
of measures 
reported? 
Description of 
participant 
characteristics 
 
Assessment 
of insulin 
misuse 
Are study-
specific 
reliability 
and 
validity 
reported? 
Are results 
analysed 
and 
reported in 
sufficient 
detail?  
 
Do the 
results 
support the 
conclusions? 
 
Overall 
Quality Rating  
(0 – 16) 
Peveler, R. C., Fairburn, 
C. G., Boller, I., & 
Dunger, D. (1992).  
 
2 2 1 2 2 0 2 2 13 (Very 
Good) 
Bächle, C., Stahl‐Pehe, 
A., & Rosenbauer, J. 
(2016).  
 
2 2 1 2 2 0 2 2 13 (Very 
Good) 
Baechle, C 
Castillo, K 
Straßburger, K 
Stahl‐Pehe, A 
Meissner, T 
Holl, R 
Giani, G 
Rosenbauer, J (2014) 
 
2 2 2 2 1 0 2 2 13 (Very 
Good) 
Ackard, D. M., Vik, N., 
Neumark-Sztainer, D., 
Schmitz, K. H., Hannan, 
P., & Jacobs, D. 
J.  (2008) 
 
2 2 0 2 2 0 2 2 12 (Very 
Good) 
Araia, E., Hendrieckx, 
C., Skinner, T., Pouwer, 
F., Speight, J., & King, 
R. M. (2017) 
2 2 1 2 1 1 1 2 12 (Very 
Good) 
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Supplementary Table 2 continued 
 
Authors and Date Is the 
research 
question or 
objective 
sufficiently 
described? 
Is an 
appropria
te study 
design 
used?  
 
Are general 
reliability 
and validity 
of measures 
reported? 
Description of 
participant 
characteristics 
 
Assessment 
of insulin 
misuse 
Are study-
specific 
reliability 
and 
validity 
reported? 
Are results 
analysed 
and 
reported in 
sufficient 
detail?  
 
Do the 
results 
support the 
conclusions? 
 
Overall 
Quality Rating  
(0 – 16) 
Falcão & Francisco 
(2017) 
 
2 2 2 2 2 0 1 1 12 (Very 
good) 
Snyder, L. L., Truong, Y. 
K. N., & Law, J. R. 
(2016).  
 
2 2 1 2 2 0 1 1 11 (Very 
Good) 
Wisting, L., Reas, D. L., 
Bang, L., Skrivarhaug, 
T., Dahl-Jørgensen, K., 
& Rø, Ø. (2017) 
 
2 2 2 2 0 0 1 1 10 
(Reasonable) 
Philippi, S. T., Cardoso, 
M. G. L., Koritar, P., & 
Alvarenga, M. (2013) 
 
2 2 1 2 1 0 0 1 9 (Reasonable) 
Schober E, Wagner G, 
Berger G, Gerber D, 
Mengl M, Sonnenstatter 
S, Barrientos I, Rami B, 
Karwautz A & Fritsch M 
(2011) 
 
1 2 0 1 2 0 0 2 8 (Reasonable) 
Grylli, V., Hafferl-
Gattermayer, A., 
Schober, E., & 
Karwautz, A. (2004) 
1 1 2 2 0 0 0 1 7 (Poor) 
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Table 2 
Summary of study characteristics in order of quality 
Authors, Date 
and Country 
Population Type of Study & 
Design 
Measures Used Results Quality 
Score 
(21) 
Bryden et al., 
(1999) 
 
United 
Kingdom 
 
Adolescents with type 1 
diabetes, followed up in young 
adulthood. All living within the 
catchment area of the study and 
all had been diagnosed with type 
1 diabetes at least a year prior to 
the study. 
 
N at baseline: 76 (43 males). 
Mean age of males at baseline = 
15.2 (SD = 2.2) 
 
N at follow up: 65 (39 males) 
Mean age of males at follow up 
= 23.7 (SD = 2.1)  
 
Longitudinal study 
using a clinician-
administered semi-
structured interview. 
EDE interview 
adapted for a 
diabetes-specific 
population*. 
 
Custom insulin 
misuse question*. 
 
Measurement of 
HbA1c 
 
 
No male participants reported insulin 
misuse for weight purposes either 
baseline or follow up.  
 
 
Excellent 
(27) 
d'Emden et al. 
(2013). 
 
Australia 
 
 
Adolescents aged 13 – 18 
recruited at a diabetes clinic.  
 
N = 124 (58 males). Mean age = 
15.4 (SD = 1.5) 
Cross-sectional self-
report written 
questionnaires. 
Youth version of 
EDE-Q † 
 
ED-3 † 
 
SDQ † 
 
Custom insulin 
misuse questions †. 
 
Measure of HbA1c  
 
15 males (25.9%) reported disturbed 
eating behaviours on at least one 
occasion.  
 
Of these, two males (3.4%) reported 
insulin misuse for weight or shape 
purposes.  
 
 
Excellent 
 32 
 
Table 2 Continued 
 
    
Authors, Date 
and Country 
 
Population Type of Study & 
Design 
Measures Used Results Quality 
Score 
(20) 
Fairburn et al. 
(1991) 
 
United 
Kingdom 
 
 
 
Young adults in the Oxfordshire 
region, who had a diagnosis of 
type 1 diabetes for at least a year 
prior to the study. 
 
N = 100 (46 men). Mean age of 
male participants = 22 (SD = 
2.2) 
Cross sectional design. 
Self-report 
questionnaires and a 
clinician-administered 
semi-structured 
diagnostic interview. 
EDE* 
 
Custom insulin 
misuse questions*.  
 
EAT † 
 
Measurement of 
Hb1Ac 
 
No males reported insulin misuse for 
weight purposes.  
Excellent 
(28) 
Neumark-
Sztainer et al. 
(2002) 
 
United States of 
America 
 
Adolescents aged 12 – 21, 
diagnosed with type 1 diabetes 
for at least a year and who were 
followed by a diabetes clinic.  
 
N = 143 (73 males). Mean age = 
15.3 (SD = 2.3) 
 
 
Cross-sectional self-
report questionnaires 
distributed by post to 
all eligible 
participants. 
Select questions from 
the following 
measures:  
 
Project EAT (Eating 
Among Teens) 
Survey † 
 
DEPS (Insulin misuse 
questions were drawn 
from this.) † 
 
FES-R † 
 
DFRQ †  
 
 
One male participant (1.4%) reported 
insulin misuse for weight purposes.  
Excellent 
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Table 2 Continued 
 
Authors, Date 
and Country 
 
Population Type of Study & 
Design 
Measures Used Results Quality 
Score 
(29) 
Wisting et al. 
(2013) 
 
Norway 
Children and adolescents with a 
diagnosis of type 1 diabetes.  
 
N = 770 (380 males). Mean age 
= 14.6 years (SD = 2.1) 
 
Cross-sectional self-
report questionnaires 
distributed manually 
when participants 
attended scheduled 
appointments at 
diabetes clinics 
DEPS-R. Two 
questions specifically 
address insulin 
misuse were used to 
operationalise the 
behaviour. † 
 
A 12-item Norwegian 
version of EAT † 
 
HbA1c was analysed. 
 
 
After overeating, 9.4% of males 
reporting underdosing insulin and 4.5% 
of males reported omitting a dose.  
 
Those who reported omitting insulin 
had significantly higher HbA1c levels, 
as well as higher scores on both the 
DEPS-R and the EAT-12. 
 
 
 
 
  
Excellent 
(30) 
Peveler et al. 
(1992).  
 
United 
Kingdom 
 
Adolescents with type 1 diabetes 
selected from the records of a 
hospital that provided specialist 
services for the target 
population. 
 
N = 76 (43 males). Mean age = 
15.2 (SD = 2.2) 
 
 
 
Cross sectional design. 
Self-report 
questionnaires and a 
clinician-administered 
semi-structured 
diagnostic interview. 
 
EQE adapted for a 
diabetic population* 
 
Custom insulin 
misuse questions. * 
 
EAT † 
 
Measurement of 
Hb1Ac 
 
 
 
 
 
 
 
No males reported insulin misuse for 
weight purposes. 
 
Very Good 
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Table 2 Continued 
 
    
Authors, Date 
and Country 
 
Population Type of Study & 
Design 
Measures Used Results Quality 
Score 
(31) 
Ackard et al. 
(2008) 
 
USA 
 
Adolescents with type 1 diabetes 
for at least one year and 
followed by a diabetes clinic.  
 
N = 143 (73 male; 70 female). 
Mean age = 15.3 (SD = 2.3 
years).  
 
 
Cross-sectional self-
report paper-based 
survey.  
 
 
Custom insulin 
misuse question in 
the context of weight 
control behaviours † 
 
 
 
1.4% of males reported omitting 
insulin in order to lose or avoid gaining 
weight.  
 
1.4% of males reported not taking 
insulin as prescribed in order to lose or 
avoid gaining weight. 
 
Very Good 
(32) 
Araia et al. 
(2017) 
 
Australia 
Adolescents with type 1 diabetes 
identified via the national 
diabetes registry. 
 
N = 477 (180 males). 
Mean age = 16 (SD = 2) 
Cross-sectional 
nationwide self-report 
web-based 
questionnaire. 
DEPS-R † 
 
BMI-SMT † 
 
Custom insulin 
misuse question †. 
 
HbA1c measurement, 
as reported by 
participants 
26 males (14%) reported omitting 
insulin on 1 – 3 days over the prior 
fortnight, and 7 males (4%) reported 
omitting insulin on 4 or more days of 
the prior fortnight.  
 
33 (18%) males scored above the cut-
off for disordered eating behaviours.  
 
It is not clear if there is a relationship 
between the male participants who 
scored above the cut-off for disordered 
eating and those who endorsed insulin 
omission. 
 
 
Very Good 
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Table 2 Continued 
 
    
Authors, Date 
and Country 
 
Population Type of Study & 
Design 
Measures Used Results Quality 
Score 
(33) 
Bächle et al. 
(2016).  
 
Germany 
This study focused specifically 
on those with “early onset” type 
1 diabetes– i.e. onset between 
birth and 4 years, and who were 
diagnosed at least 10 years prior 
to the beginning of the study.  
 
819 participants (414 males). 
Mean age = 16.3 (SD = 2.3) 
Population-based, 
Germany-wide cross-
sectional design using 
postal-based self-
report questionnaires. 
SCOFF † 
 
Custom insulin 
misuse questions † 
 
HbA1c measurement 
38 males (9.2%) scored above the cut-
off for disordered eating but did not 
endorse insulin misuse  
 
22 males (5.3%) endorsed insulin 
misuse but did not score above the cut-
off for disordered eating. 
 
8 males (1.9%) endorsed both frequent 
insulin misuse and disordered eating 
behaviours.  
 
Very Good 
(34) 
Baechle et al.  
(2014) 
 
Germany 
 
Adolescents with “early-onset” 
type 1 diabetes.  
 
N = 629 (340 males). Mean age 
= 15.3 years (SD = 1.7) 
Population-based, 
Germany-wide cross-
sectional design using 
postal-based self-
report questionnaires. 
SCOFF † 
 
Custom insulin 
misuse question † 
 
HbA1c measurement 
18.5% of male participants reported at 
least three instances of insulin 
underdosing within a week, and 6% 
reported underdosing insulin more than 
five times per week.  
 
Males who scored above the cut-off for 
disordered eating were significantly 
more likely to report insulin 
underdosing than males who did not 
(p=.018 for > five times per week; 
p=.003 for ³ 3 times per week). 
 
Males who reported insulin 
underdosing has significantly higher 
HbA1c levels than those who did not 
report insulin underdosing (p < .001) 
Very Good 
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Table 2 Continued 
 
Authors, Date 
and Country 
 
Population Type of Study & 
Design 
Measures Used Results Quality 
Score 
(35) 
Falcão & 
Francisco 
(2017) 
 
Portugal 
Young adults with type 1 
diabetes. 
 
N = 55 (18 males). 
M = 24.78 years, SD = 4.18 
 
 
Cross-sectional self-
report questionnaires 
distributed online by 
snowball sampling. 
EDE-Q † 
 
CDRS to assess body 
image dissatisfaction 
† 
 
Custom qualitative 
questionnaire 
regarding insulin 
misuse †. 
 
No male participants reported misusing 
insulin for weight purposes. 
Very Good 
(36) 
Snyder et al. 
(2016).  
 
United States 
 
Adolescents aged 12 – 20 with a 
diagnosis of type 1 diabetes for 
at least a year prior to 
recruitment, attending a diabetes 
clinic. 
 
N = 60 (29 males). Mean age = 
16.1 (SD = 2) 
Cross-sectional self-
report written 
questionnaires. 
C-DSMQ † 
 
Custom insulin 
misuse questions † 
 
Measure of HbA1c 
extracted from 
medical charts. 
Four male participants (36.4%) 
reported misusing insulin. Of those, 
one male participant reporting under-
dosing insulin, while three reported 
taking more than prescribed.  
 
Two participants who took less insulin 
than prescribed reported doing so for 
weight loss reasons, but the genders of 
these participants are not broken down 
in the paper.  
 
Eight participants reported taking more 
insulin than prescribed for the goal of 
being able to eat more food in one 
sitting. Again, the genders of these 
participants are not specified  
 
 
Very Good 
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Table 2 Continued 
 
  
 
 
  
Authors, Date 
and Country 
 
Population Type of Study & 
Design 
Measures Used Results Quality 
Score 
(37) 
Philippi et al. 
(2013) 
 
Brazil 
People with a diagnosis of type 1 
diabetes for at least a year prior 
to the study, who were receiving 
treatment from a diabetes 
service. 
 
N= 189 (48 males). Mean age = 
26.0 (SD = 9.8 years) 
Cross-sectional self-
administered 
questionnaires 
 
 
EAT † 
 
BITE † 
 
BES † 
 
Custom insulin 
misuse question †. 
 
 
No males reported intention insulin 
omission or reduction for weight 
purposes. 
Reasonable 
(1) 
Schober et al. 
(2011) 
 
Austria 
 
Children and young adults who 
had been diagnosed with type 1 
diabetes for at least one year 
prior to the study and who had 
received treatment from a 
paediatric department with 
respect to diabetes. 
 
N = 241 (103 males) 
 
Whole group mean age was not 
provided. However, all 
participants were aged between 
10 - 22. 
 
 
Cross-sectional 
design. Participants 
completed initial self-
report questionnaires 
and then took part in a 
semi-structured 
diagnostic interview 
over the telephone. 
Custom insulin 
misuse question †. 
 
DSMP † 
 
Semi-structured 
phone interview* 
 
31% of males reported intentionally 
manipulating their insulin dose.  
 
37.3% of males reported 
unintentionally over- or under-dosing 
insulin.  
 
15.5% of the whole cohort reported 
that weight loss was the primary reason 
for insulin manipulation. 
Reasonable 
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Key: EDE = Eating Disorder Examination Semi Structure Interview*; EDE-Q = Eating Disorder Examination Questionnaire †; ED-3 = Eating Disorder 3 †; SDQ = 
Strengths and Difficulties Questionnaire †; EAT = Eating Attitude Test †; DEPS = Diabetes Eating Problem Survey †;  FES-R = Family Environment Scale-
Revised †;  DFRQ = The Diabetes and Family Responsibility Questionnaire †;  DEPS-R = The Diabetes Eating Problem Survey–Revised †;  BMI-SMT = Body 
Mass Index Silhouette Matching Test †;  SCOFF = a screening tool for eating disorders †;  CDRS = Contour Drawing Rating Scale †;  C-DSMQ = The child 
version of the Diabetes Self-management Questionnaire †;  BITE = Bulimic Investigation Test of Edinburgh †;  BES = Binge Eating Scale †;  DSMP = Diabetes 
Self‐Management Profile †;  ChEDE = Child version of Eating Disorders Examination *;  EDI-2 = The Eating Disorders Inventory-2 †. 
 
Note. * denotes clinician-administered measures. † denotes self-report measures.
Table 2 Continued 
 
 
 
Authors, Date 
and Country 
 
Population Type of Study & 
Design 
Measures Used Results Quality 
Score 
(38) 
Wisting et al. 
(2017) 
 
Norway 
 
 
 
Adolescents diagnosed with type 
1 diabetes. 
 
N = 104 (44 males). Mean age = 
15.7 (SD = 1.8 years)  
Cross-sectional 
researcher-led semi-
structured interview.  
 
 
ChEDE *. Includes a 
question on 
insulin omission due 
to weight/shape 
concerns. 
 
Measurement of 
HbA1c level. 
 
No significant associations were found 
between insulin underdosing and 
weight control behaviours in males. 
Reasonable 
(39) 
Grylli et al. 
(2004) 
 
Austria 
Adolescents with type 1 
diabetes.  
 
N = 199 (103 males). Whole 
group mean age was not 
provided. 
Cross-sectional 
design. Initial self-
report questionnaires 
followed by a semi-
structured diagnostic 
interview for a 
subgroup who scored 
above a predetermined 
cut-off.  
EAT † 
 
EDI-2 † 
 
EDE – this included a 
consideration of 
insulin misuse*. 
This study only assessed insulin misuse 
in the subgroup who met the criteria for 
a subthreshold or clinical eating 
disorder. Only 1% of male participants 
met the criteria for a subthreshold 
eating disorder, and insulin misuse was 
not reported for this subgroup. 
Poor 
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Narrative Synthesis  
The available evidence suggests that males do misuse insulin for weight 
purposes, but the included studies do not allow for firm conclusions to be drawn 
about the prevalence of this behaviour. This is due in part to methodological 
differences between the included studies, including a wide range of measures used, 
lack of standardised measure for assessment of insulin misuse and study design. 
Difficulties in interpretation arose as some studies reported rates of insulin misuse 
and weight behaviours but did not adequately investigate the relationship between 
these (1,32,34,36,39).  
Within the included studies, males were well-represented in the populations 
(47.5%); however, the emphasis was on the experience of adolescents which hinders 
the generalisability of results to adult males. Equally, non-Western populations were 
not well-represented.  
When a semi-structured interview was used, men reported nil rates of insulin 
misuse for weight purposes, but higher rates were reported when a self-report design 
was utilised. Overall, reported insulin misuse rates varied from 1.4% to 37.3% for 
males, and 1.4% to 9.4% specified that it was in relation to weight control, 
suggesting that this is an area that that would benefit from further research.  
Populations 
Of the 16 included studies, there were 1995 male participants of a total of 
4205 participants with type 1 diabetes (47.5%). Twelve of the studies focused on 
children and adolescents, with mean ages ranging from 14.6 to 16.1 years. The 
remaining four studies looked at either young adults (20,33,35) or a broad age range 
(37). There was a reasonably broad spread of geographical areas covered in the 
studies: three from the United Kingdom and the United States; two from Australia, 
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Germany, Austria and Norway; and one from Brazil and Portugal. Participants were 
recruited from different sources, but generally identified through a diabetes clinic, 
hospital or a national registry.  
Study design 
Ten studies utilised a cross-sectional self-report questionnaire design, using a 
mixture of online, postal and in-clinic distributions (27–29,31–37). Four studies used 
a cross-sectional design with a mixture of self-report questionnaires and semi-
structured interviews with a researcher (1,20,30,38).  The final two studies utilised 
semi-structured interviews with no self-report aspect (21,38). Only one study used a 
longitudinal design (21).  
Measures  
A wide range of measures was used to assess insulin misuse, the majority of 
which were not validated measures. Twelve of 16 studies used customised questions, 
designed for the purposes of the study, to assess insulin misuse 
(1,20,36,37,21,27,30–35). Two studies (28,29) used questions from the Diabetes 
Eating Problems Survey (DEPS) and two used an indirect question in the semi-
structured Eating Disorder Examination (EQE) to assess insulin misuse (38,39). 
Both the DEPS and EDE are standardised validated measures, commonly used in 
routine clinical practice.  
Of those who designed their own questions, three studies only asked a single 
question about insulin misuse (32,34,37) and the remaining studies asked at least two 
specific questions regarding insulin misuse (e.g. ‘I take less insulin than I should to 
influence my shape or weight’; ‘I skip insulin shots to influence my shape or weight’ 
(27)). 
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Results 
Reported rates of insulin misuse amongst men varied from 1.4% to 37.3%, 
with males reporting insulin omission, underdosing and overdosing, and up to 9.4% 
of males reported doing so for weight purposes. Seven of 16 studies reported no 
instances of males misusing insulin for the purposes of weight control or loss 
(20,21,30,35,37–39). Six of these seven studies used a variation of the clinician-
administered EDE with additional custom insulin misuse questions, and three of 
these studies were carried out within the same research team in the UK (20,21,30). 
This may suggest that the EDE is not sensitive to detecting insulin misuse, or that 
males are less likely to disclose insulin misuse in a face-to-face setting. Additionally, 
four of those seven studies were more than 10 years old (20, 21, 30, 39), while in 
studies where insulin misuse was reported, only two of nine (28, 31) were more than 
10 years old and neither of those studies used the EDE. It is possible that older 
studies were designed in a way that made them less sensitive to the detection of 
insulin misuse in males, compared to more recent studies. 
In studies where insulin misuse for weight purposes was identified, 
interpretable prevalence rates ranged from 1.4% to 9.4% of the males who engaged 
in this. All these studies relied on self-report measures, with the exception of one 
that also included a follow-up semi-structured interview (1). Disordered eating 
behaviours were reported in 9.2% to 25.9% of males, and insulin misuse rates of 
3.4% to 14% were reported by males in those studies, but it is not clear in all cases if 
it is the same participants engaging in both or if they are different groups. Six of 16 
studies appeared to establish a relationship between insulin misuse and either weight 
and/or disordered eating behaviours (27–29,31,33,34). These studies all received a 
quality rating of “Excellent” or “Very Good”.   
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However, the results were not presented in a uniform fashion across the 
papers and it was difficult to determine the specific rates of insulin misuse for weight 
purposes in males, as this was not always clearly reported for each gender. When it 
was reported, it was based on a low number of respondents. Thus, a true estimate of 
prevalence rates cannot currently be determined from the included studies. 
Quality 
The overall quality of the included studies was generally strong, with five 
papers receiving a rating of “Excellent” (20,21,27–30) and seven receiving “Very 
Good” (31–36). The four weaker papers (rated as “Reasonable” or “Poor”) did not 
report their findings in sufficient detail, and the results did not generally support the 
conclusions, with one exception (1). Two of these papers were judged to have failed 
to adequately assess insulin misuse (38,39), which limited the interpretation of the 
results. 
Discussion 
Misuse of insulin for weight purposes has been highlighted as an area of 
particular concern by professionals involved in diabetes care, due to the risk levels 
associated with this behaviour. The results of this review indicate an inconclusive 
body of evidence regarding the degree of the behaviour in male populations. 
Notably, measures used to assess insulin misuse varied widely, with some studies 
using questions that operationalised the behaviour in a clear and defined manner, 
whilst others relied on indirect questions in pre-existing measures that were not 
specifically designed for use in a diabetic population. Several studies asked a single 
question about insulin misuse, which may have failed to capture true prevalence 
rates by not exploring the behaviour in more detail.  
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It is interesting to note that men reported low to nil rates of insulin misuse 
when the behaviour was assessed by a semi-structured interview, but in self-report 
ratings, reported rates were generally higher, up to 37.3%. This may potentially 
suggest a reluctance to discuss this behaviour directly to a healthcare professional, 
which warrants further investigation.  
Of the papers considered for inclusion in this review, 30 were excluded 
specifically because they either excluded men or did not sufficiently report the 
findings by gender. Of the papers included, several explored the results for females 
in depth, and merely acknowledged results for men with a brief sentence. The 
emphasis on the female experience in the literature is notable; however, research has 
indicated that prevalence rates of type 1 diabetes are higher for males than females in 
European populations aged 15-40, with a ratio of approximately 3:2 male:female 
(40). One possible explanation for this could be the conceptualisation of disordered 
eating, particularly relating to weight and shape, as being a predominantly female 
concern (e.g. 41). However, research indicates that between 10-25% of people with 
an eating disorder are male (42,43) and incidence rates of eating disorders in males 
are rising (18), so excluding men from research such as this should be discouraged. 
Differences have been identified in preferred body appearance between men and 
women (23,44), and this may affect how males misuse insulin compared to women. 
Studies that fail to account for this may miss these differences. Research suggests 
that gendered constructions of eating disorders may delay the identification of 
problematic eating behaviours in men (42). The same may be true of insulin misuse.  
Strengths and Limitations 
To our knowledge, this study represents the first review of this behaviour in 
males with type 1 diabetes. This alone is interesting, as type 1 diabetes affects both 
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men and women, yet men appear to be largely overlooked in research regarding 
insulin misuse for weight purposes.  
However, the findings are based on a small number of heterogeneous studies 
which could not be directly compared through statistical means, which limited the 
scope of interpretation. This was further hampered by the degree of heterogeneity 
and generally poor assessment of insulin misuse, particularly in relation to weight 
control behaviours. Whilst a reasonably broad spectrum of countries was included, 
the majority of these were developed nations with predominantly white populations, 
and it is unclear what results might be seen in low-middle income countries with 
non-Western cultures. The mean age of the populations tended to be quite young so 
this study could not capture the experiences of an older population.  
Theoretical and Clinical Implications 
These findings highlight the need for a standardised self-report measure of 
insulin misuse. Such a clinical measure should allow for a sufficiently detailed and 
non-judgemental exploration into the frequency and reasons for insulin misuse, 
taking into account the potential reluctance of an individual to discuss engaging in 
this behaviour. 
Equally, the development of tools to screen for the presence of eating 
disorder psychopathology specifically in men would be beneficial. As discussed, this 
may present in a different way between the genders and it is likely that eating 
disorder psychopathology is currently being under-diagnosed in men. A better 
awareness of the potential indicators and reasons for insulin misuse in men, 
particularly in the context of disordered eating behaviours, may aid healthcare 
professionals to identify concerns at an earlier stage.  
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Conclusions 
This systematic review is the first review to attempt to gain an understanding 
of the prevalence of insulin misuse for the purposes of weight control or loss in men 
with type 1 diabetes. Inconsistent findings emerged, with interpretation hampered by 
the lack of a specific insulin misuse measure and heterogeneity of the measures used. 
It appears that men do report insulin misuse for the purposes of weight loss or 
control through self-report measures but may be less likely to report insulin misuse 
in interview-based environments, and prevalence rates for this behaviour could not 
be determined at this time.  
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2.1 Introduction 
Insulin therapy is a requirement for people with type 1 diabetes from the 
point of diagnosis (NICE, 2015), while research suggests that just over half of those 
with type 2 diabetes require insulin therapy, and it is generally considered only after 
other treatment options have been exhausted (United Kingdom Prospective Diabetes 
Study Group, 1995).  Despite this discrepancy, much of the research on insulin 
misuse has either combined both type 1 and type 2 diabetes or focused on type 2 
diabetes. A systematic review of factors affecting insulin adherence in diabetes by 
Davies et al. (2013) included 17 studies, of which 10 focused exclusively on 
adherence in type 2 diabetes, five investigated both type 1 and type 2 diabetes and 
only a single study explored adherence in type 1 diabetes alone.  Another systematic 
review of insulin adherence measures by Stolpe, Kroes, Webb and Wisniewshi 
(2016) reviewed 58 papers (74%) that included patients with type 2 diabetes, 10 that 
combined type 1 and type 2 (13%) and just two papers that focused on type 1 
diabetes (4%). This may reflect the fact that type 2 diabetes is more prevalent in the 
general population, with up to 90% of those diagnosed with diabetes having type 2, 
but this also means that conclusions and implications for practice may not be 
applicable for people with type 1 diabetes. Insulin misuse within type 1 diabetes 
would benefit from further specific investigation. 
Another difficulty in the exploration of insulin misuse in diabetes is the lack 
of a standardised measure to assess the behaviour, resulting in a wide variety of 
methodological approaches. Two systematic reviews, examining medication 
adherence in both type 1 diabetes and type 2 diabetes, found a disparate array of 
methods, including: subjective assessments; medication monitoring systems; self-
report logbooks; biochemical measurements of blood glucose levels; and data 
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collected from pharmacy records (Clifford, Perez-Nieves, Skalicky, Reaney & 
Coyne, 2014; Stolpe et al., 2016). One standardised measure was employed in a 
small number of studies (the Morisky Medication Adherence Scale) but two different 
versions were used. Notably, the majority of these methods offer no insight into the 
reasons for insulin misuse. As can be seen from the systematic review, even research 
that is methodologically similar uses a broad range of approaches to assess insulin 
misuse with no clear preferred or gold standard measure available.  
Recently, a measure of insulin adherence has been developed (Ames, 2017).  
This measure was created in collaboration with healthcare professionals and 
individuals with diabetes and explores both frequencies and reasons for insulin 
misuse, while also exploring the potential relationship between insulin and mood and 
factors impacting motivation. Use of this measure allows for an in-depth exploration 
of insulin misuse.  
2.2 Consequences of Insulin Misuse 
Insulin misuse leads to poor glycaemic control, which can result in either 
hyperglycaemia or hypoglycaemia. As outlined previously, hyperglycaemia is a 
serious physical health concern for people with type 1 diabetes and can lead to 
complications and fatalities (Marcovecchio, 2017). Chronic complications of 
persistent hyperglycaemia include microvascular complications such as damage to 
vision, kidneys and peripheral nerves, and macrovascular complications including 
cardiovascular disease (Marcovecchio, 2017). Ultimately, chronic or persistent 
hyperglycaemia can lead to blindness, kidney failure, loss of limbs or death. 
Understanding the risk factors for poor diabetic control, including insulin misuse, is 
crucial for enabling both healthcare providers and people with diabetes to best 
manage the condition.  
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2.3 Diabetes and Mental Health 
Research suggests an association exists between psychological distress and 
type 1 diabetes. It has been proposed, as the diagnosis of type 1 diabetes commonly 
occurs in childhood or early adolescence, that the addition of the complex 
management of diabetes on top of pre-existing developmental demands of that age 
range may contribute to this increased rate of psychological distress observed 
(Danne et al., 2014). This may also be linked to an increased incidence of eating 
disorders in adolescents with type 1 diabetes (Colton et al., 2004; Neumark-Sztainer 
et al., 2002). This association is discussed further below.  
Managing diabetes may conflict with the normative demands of adolescence 
(Hamberg, 1998), and the gradual transfer of responsibility for the management of 
diabetes from parents to the adolescent may be a burden beyond the level of 
developmental maturation that results in poor adherence to the insulin regime 
(Comeaux & Jaser, 2010). Thus, psychological difficulties may begin to occur for 
children with type 1 diabetes (Reynolds & Helgeson, 2011).  
Furthermore, there is an established relationship between type 1 diabetes and 
mental health difficulties. Mood and anxiety disorders amongst adolescents with 
type 1 diabetes were found to be two to three times higher than in a community 
setting, particularly for females (Northam, Matthews, Anderson, Cameron & 
Werther, 2005). A longitudinal study estimated that over 47% of a group of 
adolescents with type 1 diabetes developed mental health difficulties within 10 years 
of diagnosis, with major depression, conduct disorder and generalised anxiety 
disorder being most common (Kovacs, Goldston, Obrosky & Bonar, 1997). 
Externalising behaviour problems (i.e. ‘acting out’) were associated with poorer 
glycaemic control in adolescents (Leonard, Jang, Savik, Plumbo & Christensen, 
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2002). Anxiety and self-rated quality of life were associated with higher blood 
glucose levels (Mortensen, 2002). A history of mental health difficulties was 
associated with poorer glycaemic control and an increased incidence of retinopathy 
(damage to the blood vessels of the retina; Cohen, Welch, Jacobson, De & Samson, 
1997).  
In adults, comorbid depression was found at significantly higher rates in 
those with diabetes compared to a community sample (adults with diabetes were 
approximately twice as likely to have comorbid depression than those without 
diabetes), and rates of depression were significantly higher in the presence of poor 
glycaemic control than well-controlled diabetes, and higher for women with diabetes 
than men (Anderson, Freedland, Clouse & Lustman, 2001). Greater depression 
symptomology is associated with poorer medication adherence (Ciechanowski, 
Katon & Russo, 2000), poorer physical health outcomes (De Groot, Anderson, 
Freedland, Clouse & Lustman, 2001) and greater levels of hyperglycaemia (Lustman 
et al., 2000). Self-efficacy appears to mediate the relationship between depression 
and glycaemic control in type 1 diabetes, but not type 2 diabetes (Sacco & 
Bykowski, 2010), and research suggests that depression may occur as a result of 
diabetes (Eaton, 2002). Taken together, this may suggest that feeling unable to 
manage the demands associated with good glycaemic control leads to depression.  
A further association was found between insulin misuse and psychiatric 
comorbidity in people with type 1 diabetes. Proportionally, over twice as many 
people with psychiatric comorbidities misused insulin when compared to a group 
with no psychiatric comorbidity (Berger et al., 2019). Those who misused insulin 
and had psychiatric comorbidity had diagnoses of specific phobia, social phobia, 
depression or eating disorders. Conversely, the group who adhered correctly to their 
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insulin regime had lower prevalence rates for psychiatric comorbidities than found in 
non-clinical samples (Berger et al., 2019). 
2.4 Diabetes-Related Distress 
As noted above, research suggests that the burden of managing diabetes 
contributes to poorer psychological outcomes. That, along with the role of self-
efficacy in mediating the relationship between depression and type 1 diabetes, 
suggests that it is possible that many of the mental health issues experienced by 
people with type 1 diabetes might be underpinned by their feelings about living with 
and managing diabetes. This has been described as diabetes-related emotional 
distress in the literature (Polonsky et al., 1995).  
Higher levels of diabetes-related distress were associated with reduced 
adherence to diabetes self-care, such as blood glucose testing, meal planning and 
insulin adherence, even when factors such as age and general emotional distress 
were controlled for (Polonsky et al., 1995). Monitoring general well-being for 
people with type 1 diabetes improved overall well-being and mental health, but did 
not improve glycaemic control (Pouwer, Snoek, Van Der Ploeg, Adèr & Heine, 
2001).  
In a group with type 2 diabetes, diabetes-related distress, but not major 
depressive disorder or depressive symptoms, was associated with glycaemic control 
(Fisher et al., 2010). Diabetes-related distress has been found to mediate the 
relationship between depression and glycaemic control in both type 1 and type 2 
diabetes (Van Bastelaar et al., 2010). Those who were depressed but did not have 
elevated diabetes-related distress were found to manage their glycaemic control 
adequately, while those with both depression and diabetes-related distress were at 
significantly increased risk of elevated HbA1c.  
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Taken together, these findings suggest that diabetes-related distress may be a 
predictor of poorer glycaemic control, which may also be related to insulin misuse. 
Diabetes-related distress should be considered when investigating the reasons for 
insulin misuse. 
2.5 Diabetes and Eating Disorders 
The comorbidity of eating disorders and type 1 diabetes will be discussed in 
detail the next chapter; however, this subsection provides an overview of the types of 
eating disorder commonly diagnosed in people with type 1 diabetes, along with 
published guidance about the comorbidity of insulin misuse and eating disorder 
psychopathology.  
The Diagnostic and Statistical Manual of Mental Disorders, 5th Edition 
(DSM-5, American Psychiatric Association [APA], 2013, p. 329) defines an eating 
disorder as “… a persistent disturbance of eating or eating-related behaviour that 
results in the altered consumption or absorption of food and that significantly 
impairs physical health or psychosocial functioning”.  Several different types of 
eating disorder defined by the DSM-5 and relevant to this study include: 
Anorexia Nervosa (AN). This is defined as a persistent reduction in caloric 
intake, intense fear of gaining weight, and a disturbance in perceived body shape or 
weight (APA, 2013);  
Bulimia Nervosa (BN). Defined as recurrent binge eating with inappropriate 
compensatory behaviours such as self-induced vomiting or laxative misuse, and 
disproportionate impact of body weight and shape on self-evaluation (APA, 2013);  
Binge-Eating Disorder (BED). This is characterised by frequent 
consumption of a large amount of food in a short period of time, without 
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compensatory purging (APA, 2013). Binges are generally a distressing experience 
for the person, and they feel unable to stop or control their eating.  
Other Specified Feeding or Eating Disorder (OSFED). This is a new 
diagnostic category in the DSM-5 (APA, 2013) and replaces the previous category of 
Eating Disorders Not Otherwise Specified (EDNOS). This is understood as 
occurring when symptoms of feeding or eating disorders do not meet clinical criteria 
for the above categories or are a mixture of several of the above (APA, 2013).  
Subthreshold Eating Disorder. This term may be used when the eating 
disturbance is milder in severity or less frequent in occurrence than specified in the 
diagnostic criteria of the above categories (Jones et al., 2000).  
The DSM-5 further references the omission of insulin within eating 
disorders: “Individuals with anorexia nervosa may misuse medications, such as by 
manipulating dosage, in order to achieve weight loss or avoid weight gain. 
Individuals with diabetes mellitus may omit or reduce insulin doses in order to 
minimize carbohydrate metabolism” (APA, 2013, p.341). The National Institute for 
Health and Care Excellence (NICE) released guidelines which specifically refer to 
the comorbidity of eating disorders and T1DM (NICE, 2015; 2017): “…be alert to 
the possibility of bulimia nervosa, anorexia nervosa and insulin dose manipulation in 
adults with T1DM …” and “Address insulin misuse as part of any psychological 
treatment for eating disorders in people with diabetes”. 
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Abstract 
OBJECTIVE – This study investigates the prevalence rates of insulin misuse by 
adults with type 1 diabetes, and explores the relationships between insulin misuse 
and gender, eating disorder psychopathology and diabetes-related distress.  
RESEARCH DESIGN AND METHODS – A cross-sectional, web-based survey 
was completed by 219 adults with type 1 diabetes living in the United Kingdom, 
recruited online. Participants completed a measure of insulin misuse, the Eating 
Disorder Examination Questionnaire, Body Shape Questionnaire and the Diabetes 
Distress Scale. Data were analysed statistically and compared using χ2, independent 
samples t-tests, logistic regression and MANOVA.  
RESULTS – Insulin misuse was reported by over 60% of respondents. Women were 
significantly more likely to misuse insulin than men overall and specifically for 
weight loss and control. Those who had a current or historical diagnosis of an eating 
disorder were more likely to misuse insulin for weight loss or control than those with 
no history of an eating disorder. People who reported insulin misuse had 
significantly higher levels of disordered eating behaviours, more negative feelings 
about body shape and greater degrees of diabetes-related distress. Diabetes-related 
distress was the only predictor of insulin misuse. 
CONCLUSIONS – Disclosure of insulin misuse by adults with type 1 diabetes may 
be suggestive of the presence of disordered eating behaviours or clinical levels of 
diabetes-related distress. Insulin misuse occurs across the range of eating disorder 
categories and should be considered as a discrete difficulty. Insulin misuse should be 
investigated routinely in clinical practice.  
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Amongst people with type 1 diabetes, the misuse of insulin is a particularly 
concerning behaviour, as it can cause a number of serious health concerns (1). 
Insulin misuse typically refers to either deliberately under-dosing, over-dosing or 
omitting a scheduled dose of insulin (2). Under-dosing or omitting a dose can lead to 
hyperglycaemia, and significant and rapid weight loss may be seen through a 
combination of dehydration and caloric restriction (3).  
Eating disorders are characterised by disturbed eating behaviours, such as 
severe restriction or rapid bingeing and purging of food, with the aim of weight loss 
or control, preoccupation with body shape and size, and distortion of body image (4). 
Eating disorders have high comorbidity and mortality rates (5,6). The comorbidity of 
eating disorders and type 1 diabetes was first identified in the 1980s (7,8). Herpertz 
et al. (9) found a point prevalence for eating disorders of 7.9% for females and 2% 
for males with type 1 diabetes, with an average lifetime prevalence of 10% across 
genders, and 4.1% of participants reported insulin misuse (9).  
Two meta-analyses found increased prevalence rates of Bulimia Nervosa 
(BN) and Eating Disorder Not Otherwise Specified (EDNOS) in women with type 1 
diabetes, compared to controls, and both failed to find a significant difference in 
rates of Anorexia Nervosa (AN) between the groups (10,11). Nielsen (10) reported 
that rates of insulin misuse were increased when an eating disorder co-existed with 
type 1 diabetes. More recently, NICE released guidelines which specifically refer to 
the comorbidity of eating disorders and type 1 diabetes, with reference to insulin 
misuse (12). 
It has been proposed that the demands of managing type 1 diabetes 
necessitate heightened attention to food, dietary restraint and weight, which may 
contribute towards the association between disordered eating and type 1 diabetes 
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(13). Adolescent girls with type 1 diabetes are heavier than their non-diabetic peers, 
on average (14–16), possibly due to insulin use (17). Prior to diagnosis, many people 
with type 1 diabetes experience weight loss, which is typically regained when insulin 
therapy begins (18). This likely marks the beginning of the mental association 
between insulin therapy and weight gain for people with type 1 diabetes, which may 
lead to insulin misuse as a method of weight loss or control if body weight or shape 
dissatisfaction is a concern (19,20).  
Prevalence rates of insulin misuse vary significantly, with limited previous 
literature reporting rates from 17%–59% (1,9,21,22). Two studies identified weight 
loss as a reason for insulin misuse in 6% – 7.5% of respondents (1,9). A recent 
systematic review reported weight as a reason for insulin misuse in 4.1% – 58% of 
people with type 1 diabetes who reported misuse (23). When co-morbid eating 
disorders were present, rates of misuse varied from 47.9% – 90%, and rates were 
higher for women than for men (23). Increased rates of insulin misuse are associated 
with a threefold increase in the risk of mortality in adult women with type 1 diabetes, 
exacerbated by the presence of disordered eating symptoms (24). Insulin misuse for 
the purposes of weight loss has been referred to as “diabulimia” (25).  
In addition, other reasons for insulin misuse identified in previous research 
are: lifestyle burden and lack of flexibility of insulin regimen (26); forgetting (27); 
embarrassment (28); emotional distress related to diabetes and as an adaptive 
response to fluctuating blood sugar levels (22). Many of these may be categorised as 
diabetes-related distress (29). 
To date, little research has explored the prevalence of insulin misuse within 
eating disorder psychopathology in people with type 1 diabetes specifically. Many 
studies have included people with type 2 diabetes (21,26,30) which may mask the 
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finer details of the individual groups. Further, the majority of research has focused 
on an adolescent female population. This study aims to gain a better understanding 
of the relationship between insulin misuse, disordered eating and perception of body 
shape in both male and female adults with type 1 diabetes. The impact of diabetes-
related distress on insulin misuse will be explored. As such, the research questions 
that this study aims to address are: 
In adults with type 1 diabetes: 
1. What are the rates of insulin misuse reported? 
2. Is there a relationship between gender and insulin misuse? 
3. Is there a relationship between eating disorder psychopathology and 
insulin misuse? 
4. Is there a relationship between perception of body shape and insulin 
misuse? 
5. Is there a relationship between diabetes-related distress and insulin 
misuse? 
These findings may help to guide a deeper understanding of some of the 
issues that people with type 1 diabetes experience and may contribute to better 
support and treatment services being developed. 
Research Design and Methods 
Design 
A cross-sectional, web-based survey design was employed, consisting of 
validated self-report measures designed to capture demographic information, insulin 
misuse, diabetes-related distress, disordered eating, and body shape perception.  
Participants and Procedure 
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 Participants were recruited through online communities, primarily through 
Twitter or diabetes information and support organisations such as diabetes.org.uk 
and Diabetics with Eating Disorders (DWED), via an advertisement for the study 
and subject to gatekeeper’s permission where necessary.  
Inclusion/Exclusion criteria. Participants were eligible to participate if they 
self-described as being aged 18 or over, with a diagnosis of Type 1 diabetes and on a 
prescribed insulin regime. They were required to be at least one-year post-diagnosis, 
as people who have been prescribed insulin for less than one year may not have 
settled into a routine with insulin management and may mismanage their insulin 
unintentionally.  Additionally, participants were required to reside within the UK, as 
this removed a potential confound of cost or resources as a barrier to accessing 
insulin.  
People with a diagnosis of type 2 diabetes were excluded from the study, as 
the pathophysiology and treatment of the two illnesses are quite different. For 
example, as those with type 2 diabetes still produce some degree of insulin naturally, 
misuse of insulin is likely to have less of an immediate impact than for those with 
type 1 diabetes, who produce no insulin naturally (21).  
Potential participants were provided with a link to the study which provided 
detailed information about the study, details of informed consent and their right to 
withdraw. When the survey was completed, or participants chose to exit, a debrief 
page was presented with signposts towards various supports and resources. 
Participants were offered the opportunity to receive a brief summary of findings 
from the study and given the chance to win a £25 Amazon gift voucher, both of 
which required an email address to be supplied through separate surveys, so as to 
protect the confidentiality of responses. Ethical approval for this study was granted 
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by the chair of the Ethics Committee for the Faculty of Medicine and Health 
Sciences at the University of East Anglia. 
Statistical Analysis 
Prior to beginning the study, an estimate of the minimum number of 
participants required was calculated using statistical power tables (31) and G*Power 
version 3.1. Based on previous research (22), a medium effect size (.5) was used to 
calculate sample sizes with a power of .8 (31), which generated a necessary sample 
size of 208. All analyses were adequately powered. 
Data were analysed using IBM SPSS Statistics for Mac version 25.  
Measures 
Demographic Information. This section collected basic demographic 
information, including age; gender; country of residence; and current or historical 
diagnosis of an eating disorder. The data were screened to ensure participants met 
the inclusion criteria. 
Insulin Measure. A 16-item questionnaire has been designed to assess rates 
and reasons for insulin misuse (22).  
Eating Disorder Psychopathology. The Eating Disorder Examination-
Questionnaire (EDE-Q) assesses eating disorder psychopathology, and data from this 
measure was key to informing the primary research questions. It was designed as a 
self-report version of the interview-based Eating Disorders Examination (EDE; 32), 
which is considered to be the gold standard measure (33). The EDE-Q assesses four 
subscales:  Restraint, Eating Concern, Shape Concern, and Weight Concern. It was 
found to be an adequate alternative to the EDE (32).  
Body Shape Questionnaire (BSQ). The Body Shape Questionnaire is a 34-
item self-report measure, designed to assess concerns regarding body shape and the 
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phenomenological experience of “feeling fat” (34). The BSQ targets body image as a 
central feature of both AN and BN and thus is a useful supplementary measure of 
eating disorder psychopathology.  
Diabetes Distress. The Diabetes Distress Scale (29) is a 17-item scale 
designed to measure diabetes-related emotional distress via four domains: emotional 
burden, physician distress, interpersonal distress and regimen distress. This measure 
was included on the basis of results from Ames (22), which identified diabetes-
related emotional distress as a key reason for insulin omission in type 1 diabetes. 
Inclusion in this study allowed for further investigation of its role. 
Results 
Participant Characteristics 
A total of 224 people completed the survey. Screening of the responses 
identified five participants who did not live in the United Kingdom, and these 
datasets were removed as they failed to meet the inclusion criteria. The remaining 
219 datasets were included in the final analysis, comprising of 171 female 
respondents (78%) and 47 males (21.5%). The majority of respondents were aged 18 
– 44 years (73.1%), 30% had completed an undergraduate degree and a further 22% 
had completed a postgraduate degree. The mean age of diagnosis of type 1 diabetes 
was 18 years (SD=12.96). The majority (51%) had been prescribed an insulin regime 
for over 15 years, 20% had been prescribed for 1-5 years and the remainder for 6-15 
years. Insulin pumps were used by 42%, while 54% administered multiple daily 
injections of insulin (basal-bolus). Table 1 details the reported rates of eating 
disorders within the population.  
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Supplementary Table 1 
Participant Characteristics 
Variable  N % 
Age 18-24 60 28% 
25-34 54 25% 
35-44 44 21% 
45-54 35 16% 
55-64 16 7% 
65 or older 6 3% 
Gender Female 171 78% 
Male 47 21.5% 
Did not respond 1 0.5% 
Highest level of 
education completed 
Some secondary school 2 1% 
GCSEs or equivalent 8 4% 
A-Levels or equivalent 29 14% 
Trade/technical/vocational 
training 
15 8% 
Some university 27 12.5% 
Undergraduate degree 65 30% 
Some postgraduate 18 8% 
Postgraduate degree 49 22% 
Other 1 0.5% 
Current Employment 
Status 
Full-time student 28 14% 
Part-time employee 32 14.5% 
Full-time employee 102 48% 
Self-employed 15 7% 
Unemployed 16 7.5% 
Other 20 9% 
Length of time 
prescribed an insulin 
regime 
1-5 years 44 21.5% 
6-10 years 31 14.5% 
11-15 years 30 14% 
More than 15 years 109 50% 
Type of insulin 
regime 
Twice-daily injections 5 3% 
Multiple daily injections 118 54% 
Insulin pump 92 42% 
Other 2 1% 
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Table 1 
Reported rates of eating disorder diagnoses 
Variable  Women Men Overall 
  N (%) N (%) N (%) 
Have you ever been 
formally diagnosed with 
an eating disorder? 
Yes – Current 8 (4.7%) 1 (2.1%) 9 (4.1%) 
Yes – Historical 27 (15.8%) 0 27 (12.3%) 
No 135 (78.9%) 46 (97.9%) 183 (83.6%) 
 
If yes, which eating 
disorders have you been 
diagnosed with? 
(Multiple choice 
question) 
Anorexia Nervosa 9 (23.7%) 0 9 (23.7%) 
Bulimia Nervosa 9 (23.7%) 0 9 (23.7%) 
Binge-Eating 
Disorder 
3 (7.9%) 0 3 (7.9%) 
Eating Disorder Not 
Otherwise Specified 
12 (31.6%) 1 (2.6%) 13 (34.2%) 
Other 7 (18.4%) 0 7 (18.4%) 
 
Two participants believed they have an undiagnosed eating disorder, both 
referring to it as diabulimia.  
Results of Insulin Measure 
For the sake of brevity, the act of omitting an insulin dose or intentionally 
taking an incorrect amount will be referred to as ‘insulin misuse’. Nearly half of 
respondents (47%) reported insulin omission and 60.7% reported taking too much or 
too little. Concerningly, over half of respondents (52%) said they would not tell their 
diabetes team about insulin misuse, were it to occur. Detailed results are presented in 
Table 1. 
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Table 2 
Summary of Insulin Use Questionnaire Findings 
Variable Women Men Overall 
N % N % N % 
 
Omitting doses Yes 85 49.7 17 36.2 103 47 
No 
 
86 50.3 30 63.8 116 53 
Frequency in past 7 
days 
Once 29 17 5 10.6 34 15.5 
2 – 4 times 28 16.4 10 21.3 39 17.8 
5 – 6 times 11 6.4 2 4.3 13 5.9 
7 or more times 
 
15 8.8 -- -- 15 6.8 
Reason for omitting 
* 
Other things took priority at the time 53 31 11 23.4 65 29.7 
Negative feelings around diabetes 31 18.1 4 8.5 36 16.4 
As a method of weight control 24 14 1 2.1 25 11.4 
As a method of weight loss 18 10.5 2 4.3 20 9.1 
Avoidance or fear of physical effects 24 14 2 4.3 26 11.9 
Anticipating low blood sugar and 
planning around this 
 
19 11.1 8 17 27 12.3 
Taking more or less 
insulin than 
prescribed 
No 61 35.7 24 51.1 86 39.3 
Yes – More 18 10.5 3 6.4 21 9.6 
Yes – Less 43 25.1 3 6.4 46 21 
Yes – Both 
 
49 28.7 17 36.2 66 30.1 
Frequency in past 7 
days 
Once 24 14 5 10.6 29 13.2 
2 – 4 times 58 33.9 13 27.7 71 32.4 
5 – 6 times 13 7.6 2 4.3 15 6.8 
7 or more times 15 8.8 3 6.4 18 8.2 
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Table 2 Continued 
Variable Women Men Overall 
N % N % N % 
 
Reason for taking 
incorrect dosage* 
Other things took priority at the time 38 22.2 6 12.8 44 20.1 
Negative feelings around diabetes 32 18.7 6 12.8 38 17.4 
As a method of weight control 18 10.5 1 2.1 19 8.7 
As a method of weight loss 18 10.5 2 4.3 20 9.1 
Avoidance or fear of physical effects 44 25.7 5 10.6 49 22.4 
Anticipating low blood sugar and 
planning around this 
 
39 22.8 10 21.3 49 22.4 
Do you consider 
insulin misuse a 
problem for you 
Yes 59 34.5 12 25.5 72 32.9 
No 
 
 
111 64.9 34 72.3 145 66.2 
Would you, or do 
you, tell you 
diabetes team 
about missing 
doses? 
Yes 49 28.7 16 34 65 29.7 
No 63 36.8 7 14.9 71 32.4 
Not applicable (I do not miss doses) 58 33.9 23 48.9 81 37 
Note. *This was a multiple-choice option   
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Chi-squared tests for independence (with Yates Continuity Correction) 
indicated significant associations between gender and insulin misuse. Overall, 
women were significantly more likely to report the misuse of insulin overall, c2 (1, N 
= 218) = 4.72, p = 0.03, phi = .159. When insulin misuse data were separated out 
into those who misused purely for weight loss or control, women again were 
significantly more likely to misuse than men, c2 (1, N = 218) = 4.5, p = .034, phi = 
.159. For reasons other than weight, no significant associations were seen between 
insulin misuse and gender, c2 (1, N = 185) = 2.8, p = .095, phi = .136.  
Of those who reported a current or historical diagnosis of an eating disorder 
(N = 36), 20 people (56%) reported omitting insulin doses for the purposes of weight 
loss (N = 13) and/or control (N = 17). Of those, ten people reported omitting insulin 
for both weight control and loss. This behaviour was reported across the range of 
eating disorders: EDNOS (N = 11); “Other” (N = 4); AN (N = 4); BN (N = 3); and 
BED (N = 1). However, for those who had never been diagnosed with an eating 
disorder (N = 181), the majority (93.4%) did not omit insulin for weight control or 
loss. Of the remainder, five people reported omitting doses for weight control, four 
for weight loss and three reported omitting doses for both weight loss and control.  
Between-Groups Comparisons 
Group comparisons were carried out to investigate differences between those 
who reported misusing insulin and those who did not. A Bonferroni correction was 
applied for the 11 variables in the analysis, resulting in a statistical significance 
threshold of p < .0045 (.05 ÷ 11). This did not impact the significances observed.  
EDEQ. People who misuse insulin indicated significantly higher levels of 
disordered eating behaviours (M = 1.95, SD = 1.32) than those who did not misuse 
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insulin (M = 1.32, SD = 1.04), t (171.517) = -3.532, p = .001, d = -.54. Full details of 
these results can be seen in Table 3.  
BSQ. Participants who misuse insulin had higher scores on the BSQ (M = 
101.76, SD = 48.40) than those who do not misuse insulin (M = 71.89, SD = 36.18), 
indicating that people who misuse insulin have significantly more negative feelings 
about their body shape and a greater feeling of “fatness”, t (178.972) = -5.102, p ≤ 
.001, d = -.76. 
DDS. Overall, people who misuse insulin had significantly greater degrees of 
diabetes-related distress (M = 3.39, SD = 1.20) than those who did not misuse 
insulin (M = 2.19, SD = 1.07), t (217) = -7.181, p ≤ .001, d =.98. Full details can be 
seen in Table 3.  
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Table 3 
Differences between insulin misuse group and no insulin misuse group on results for EDEQ, BSQ and DDS 
 Insulin Misuse (N = 148) No Insulin Misuse (N = 71)  
 M SD M SD Result p Cohen’s d 
        
EDEQ Restraint 
 
1.81 1.66 1.70 1.49 t (217) = -.460 .646 -.06 
EDEQ Eating Concern 1.57 1.54 .66 .92 t (206.795) =    -5.452 * ≤ .001 
 
-.76 
EDEQ Shape Concern 2.42 1.43 1.57 1.28 t (217) = -4.237 ≤ .001 
 
-.58 
EDEQ Weight Concern 2.02 1.33 1.35 1.11 t (163.102) = -3.920 * ≤ .001 
 
-.61 
EDEQ Global 
 
1.95 1.32 1.32 1.04 t (171.517) = -3.532 * .001 -.54 
Total BSQ 
 
101.76 48.40 71.89 36.18 t (178.972) = -5.102 * ≤ .001 
 
-.76 
DDS Total 
 
3.39 1.20 2.19 1.07 t (217) = -7.181 ≤ .001 
 
-.98 
DDS Emotional Burden 
 
3.97 1.44 2.57 1.35 t (217) = -6.845 ≤ .001 
 
-.93 
DDS Physician-related distress 
 
2.83 1.50 2.03 1.47 t (217) = -3.751 ≤ .001 
 
-.51 
DDS Regimen-related Distress 
 
3.38 1.45 1.92 1.04 t (184.184) = -8.445 * ≤ .001 
 
-1.25 
DDS Interpersonal Distress 3.19 1.50 2.19 1.29 t (158.921) = -5.098 * ≤ .001 
 
-.81 
        
* = unequal variances assumed 
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Predictive Analysis 
To determine the degree to which total scores on the EDEQ, BSQ and DDS, 
along with the impact of gender, could predict the likelihood that an individual will 
misuse insulin, a binomial logistic regression was performed. The model was found 
to be statistically significant, c2(4) = 50.935, p < .0005. It explained 29.1% 
(Nagelkerke R2) of the variance in insulin misuse and correctly classified 76.1% of 
cases. Specificity was 53.5% and sensitivity was 87.1%. The positive predictive 
value was 79.5% and the negative predictive value was 66.67%. Of the predictor 
variables, neither scores on the EDEQ or BSQ, nor gender, were statistically 
significant (as shown in Table 4). Diabetes-related distress was a significant 
predictor of insulin misuse, with higher scores associated with increased likelihood 
of insulin misuse.  
Table 4 
Logistic Regression Predicting Likelihood of Insulin Misuse  
 B SE Wald df p Odds 
Ratio 
95% CI for Odds 
Ratio 
 Lower Upper 
EDEQ -.414 .270 2.355 1 .125 .661 .390 1.122 
BSQ .012 .008 2.457 1 .117 1.013 .997 1.028 
DDS .898 .188 22.745 1 .000 2.455 1.697 3.551 
Gender .217 .405 .287 1 .592 1.242 .562 2.748 
Constant -2.284 .522 19.159 1 .000 .102   
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One-way multivariate analysis of variance (MANOVA) 
To investigate differences between those who do not misuse insulin, those 
who misuse for weight purposes and those who misuse for other reasons on scores of 
the EDEQ, BSQ and DDS respectively, a MANOVA was performed. Tukey HSD 
post-hoc analyses indicated those who misuse insulin for weight purposes had 
significantly higher mean scores on the EDEQ than those who do not misuse insulin 
at all (p < .0005) and those who misuse insulin for non-weight reasons (p < .0005). 
However, EDEQ mean scores were not statistically significantly different between 
those who misuse insulin for non-weight purposes and those who do not misuse 
insulin (p = .119). There was a statistically significant difference between all groups 
for scores on the BSQ and DDS measures (p < .01), with the highest scores for all 
seen in the group that misuse insulin for weight purposes, followed by the misuse for 
non-weight reasons group.  
Discussion 
This study investigated relationships between insulin misuse in adults with 
type 1 diabetes and eating disorder psychopathology, perception of body shape, 
diabetes-related distress and gender. Overall, 47% of respondents reporting omitting 
insulin doses at times, and 60.7% indicated that they took either more or less than 
prescribed on occasion. Women were significantly more likely to report insulin 
misuse than men overall (p = 0.03) and specifically for weight purposes (p = .034). 
However, when those who misused insulin for weight purposes were removed from 
the sample, no significant associations were found between gender and insulin 
misuse. This suggests that insulin misuse for weight purposes amongst women is a 
significant contributor to the gender differences observed. Diabetes-related distress 
was the only predictor of insulin misuse. Those who misused insulin for weight 
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purposes had significantly higher scores on all measures, particularly on the EDEQ 
where no significant differences in scores were found between those who misuse 
insulin for non-weight reasons and those who don’t misuse at all.  
Previous research has suggested varying prevalence rates of insulin misuse, 
from 17.7% to 59% (1,9,21,22). The results of this study tally with the higher rates 
reported (21,22). Furthermore, the behaviour occurred relatively frequently. In the 
seven days prior to responding to the survey, 17.8% of respondents omitted an 
insulin dose 2-4 times. A further 6.8% had done so at least seven times. For taking 
an adjusted dose of insulin, frequencies rose: 32.4% had done so 2-4 times in the 
past week, and 8.2% had done so seven or more times. This is in line with findings 
from previous research (21).  
A diagnosis of an eating disorder, either current or historical, was identified 
in 16.4% of respondents. Broken down by gender, this represents 2% of male 
respondents and 20.5% of female respondents. Lifetime prevalence rates for females 
with type 1 diabetes are higher in this study than in previous studies (9,11), but the 
rates for men agree with those reported by Herpertz and colleagues (9). However, 
very limited research exists as to the prevalence rates of eating disorders in adult 
males with type 1 diabetes, to the extent that males were excluded from a meta-
analysis of eight studies due to insufficient sample size (11).  
Those who had a current or historical diagnosis of an eating disorder had 
proportionally higher rates of omitting insulin doses for weight purposes than those 
with no diagnosis of an eating disorder (56% compared to 6.6%). This was seen 
across the various eating disorders diagnosed. Across the entire sample, people who 
misused insulin showed significantly higher degrees of eating disorder 
psychopathology, particularly the group who reported misuse for weight purposes, as 
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measured by the EDEQ, than those who did not report insulin misuse, in line with 
previous research (35). Those who present with type 1 diabetes with comorbid eating 
disorders are considered a particularly difficult group to treat effectively (36), and 
they do not appear to demonstrate improved glycaemic control or reduction in 
insulin misuse rates following standard treatment for eating disorders (37). This, 
taken together with the current findings, suggests that insulin misuse for weight 
purposes is not a characteristic of a particular eating disorder, but may be better 
understood as a discrete disorder in itself, as suggested by Allan and Nash (25).  
The results indicate a relationship between insulin misuse and eating disorder 
psychopathology that is not characterised by food restriction. Were insulin misuse 
not a marker of eating disorder psychopathology, it would be expected that no 
significant differences would emerge between the insulin misuse group and those 
who use correctly. In this case, however, the presence or absence of insulin misuse, 
and the reasons for it, appear significantly related to the degree of eating disorder 
psychopathology endorsed by respondents. No significant differences were seen 
between the groups on the Restraint subscale of the EDEQ, which measures 
behaviours such as restricting food intake or going without food for long periods to 
influence weight or shape. This suggests that both groups have similar eating 
patterns and insulin misuse is not due to a discrepancy in the quantity of food eaten. 
Meanwhile, significant differences were seen between the groups for the subscales 
of Eating Concern, Shape Concern and Weight, with those who misuse insulin 
reporting significantly higher level of concern on these scales. A similar finding was 
seen with those who misuse insulin reporting greater levels of “feeling fat” and 
negative perceptions of their body shape.  
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However, it may be important to note that a dichotomy appeared to emerge 
between those who misuse insulin for weight purposes and those who misuse for 
other reasons, which replicates a trend observed by Polonsky et al. (35). Diabetes-
related distress levels were significantly higher amongst those who misuse insulin 
than those who don’t, and it was the only significant predictor of insulin misuse 
identified from the variables. The authors of the DDS suggest that a mean score 
greater than three represents distress that is worthy of clinical attention (29). The 
insulin misuse group had mean scores exceeding three on all but one scale of the 
DDS (physician-related distress), which suggests that a clinically concerning level of 
diabetes-related distress is experienced by people who misuse insulin, with the 
highest score being seen for the Emotional Burden subscale (M = 3.97, SD = 1.44). 
The questions that comprise this subscale may tap into a feeling of loss of control 
over one’s life or health as a result of living with diabetes (e.g. “Feeling 
overwhelmed by the demands of living with diabetes” and “Feeling that I will end up 
with serious long-term complications, no matter what I do”).  
Research suggests that those who misuse insulin have lower levels of both 
general and diabetes-related self-efficacy (22), which is the belief of an individual 
that they can successfully execute and complete a behaviour in order to achieve the 
desired outcome (38), and these findings appear to support that. Further research 
suggested that insulin misuse is more likely when an individual feels that they have 
broken a strict dietary rule (39). Attempting to adhere to strict rules may decrease 
perceived self-efficacy, leading to a greater sense of being unable to manage the 
demands of diabetes and increasing the likelihood of insulin misuse. Targeting an 
individual’s belief about their ability to manage diabetes, to empower them to feel 
more confident, may be a useful intervention in this scenario. 
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Strengths and Limitations 
The findings of this study are strengthened by the large sample size, and by 
the inclusion of men, as much of the previous research was limited to females. 
However, men are underrepresented in the sample, and the results may not be 
generalisable to men with type 1 diabetes as a whole. The male sample size also 
limited the analyses available, as many analyses could not be carried out on males 
exclusively due to lack of statistical power. This limited investigations into insulin 
misuse in men and between-groups differences for men and women. The online 
recruitment strategy may have captured a group who are more likely to seek help and 
peer support, which may have influenced the findings. Equally, those who do not 
actively engage with online diabetes support communities were unlikely to be well 
represented in the sample.  
The measures used may have been more appropriate for a female sample and 
may have failed to capture male concerns adequately, particularly the Body Shape 
Questionnaire. The shape and weight concerns of men and women may differ, with 
women aiming for thinness and men preferring to gain muscle (40); thus, caution 
must be exercised in interpreting the results for men on the basis of the measures 
used. Similarly, neither the EDEQ or BSQ were adapted for a diabetes-specific 
population, and this may have impacted the specificity of the data collected. The 
study also relied on anonymous self-report methods. This reduced participant burden 
and may have encouraged honest reporting, but it also prevents elaboration and 
clarification if needed. Finally, the cross-sectional nature of the study limits the 
interpretation of causality.  
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Clinical Relevance 
This study has a number of implications for research and practice. It expands 
on the very limited body of evidence regarding insulin misuse in males and also 
provides insight into an adult population, which is also under-studied in this regard. 
Further research that specifically addresses insulin misuse practices in males would 
be valuable.  
This study highlights the importance of understanding insulin misuse in 
people with type 1 diabetes. The disclosure of insulin misuse may be suggestive of a 
risk of disordered eating or difficulties managing the burden of diabetes and should 
be investigated further. Use of screening tools to identify the frequency and reasons 
for insulin misuse may be helpful for healthcare professionals working in both 
diabetes and eating disorder teams.  
There is some evidence to suggest that insulin misuse for weight loss or 
control is a valid construct and should be considered separately from current eating 
disorder diagnostic labels. Patients who misuse insulin should be offered tailored 
treatment approaches where possible, designed to target the underlying reasons for 
insulin misuse. Given the relationship with diabetes-related distress, taking a less 
rigid approach to insulin management may be beneficial, as it may support some 
people in feeling better able to manage the demands of diabetes. Finally, given the 
high rates of diabetes-related distress experienced by those with type 1 diabetes, 
along with the increased prevalence of insulin misuse and eating disorder 
psychopathology, a multidisciplinary approach should be used to support both the 
physical and mental health of people with type 1 diabetes.  
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This chapter provides further information on the methodology employed in the 
empirical paper, including information on ethical considerations, procedure and 
statistical considerations.  
4.1 Ethical Considerations 
A number of ethical issues were considered for this study.  
4.1.1 Ethical Approval. Ethical approval for this study was granted by the 
Faculty of Medicine and Health Sciences (FMH) at the University of East Anglia 
(UEA). See approval letter attached in Appendix B. 
4.1.2 Language. The survey was initially entitled “Exploring the relationship 
between insulin misuse and eating attitudes and behaviour in adults with type 1 
diabetes”. Following feedback from participants at an early stage of the recruitment 
process regarding the perception of the term “misuse” as blaming, an amendment 
was submitted to the Chair of FMH Ethics requesting permission to alter the survey 
wording to “Exploring the relationship between insulin use and eating attitudes and 
behaviour in adults with type 1 diabetes”. Permission for this amendment was 
granted, and the letter confirming this is attached in Appendix C.  
4.1.3 Confidentiality. Participants were informed as to the anonymous 
nature of the study and information was provided regarding how their responses 
would be stored in a confidential and secure manner on the participant information 
sheet (PIS; Appendix D). No personally identifying information was required. 
Participants had the option of providing their email addresses at the end of the study 
for a chance to win a £25 Amazon gift card, and to receive a brief copy of the 
findings. The PIS outlined that the winner of the gift card would be chosen by a 
random lottery and contacted via the email address provided once the data collection 
had been completed. In order to ensure and protect anonymity, this information was 
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stored separately to the survey responses in a secure, password-protected file. This 
file will be destroyed as soon as those who have requested a copy of the results have 
been contacted by email. 
4.1.4 Informed Consent. The PIS included information regarding the nature 
and duration of the study to allow for informed consent. Contact details for the 
author were provided to answer any questions that participants may have at any 
point. Participants read a short online consent form prior to beginning, in which they 
were asked to tick a box to indicate their understanding and consent (Appendix E).  
4.1.5 Withdrawal. It was made clear that participants were free to withdraw 
from the study at any time they wish with no repercussions, by using the “Exit This 
Survey” button that was displayed on every page of the survey. Due to the inability 
of the author to identify specific responses, it was not possible to remove the data of 
any individual respondent once it had been submitted, but this was not requested by 
any participant.  
4.1.6 Debriefing and Protection of Participants. A short debrief page was 
provided at the end of the survey with contact details for the author (Appendix F). 
The measures used in the study had the potential to cause mild distress for 
participants. Broad information regarding the nature of the measures was provided as 
part of the informed consent procedure. Along with their right to withdraw, the PIS 
clearly outlined the right of participants to not answer any question that they did not 
wish to. Furthermore, as part of the debrief, signposting towards support services 
was included. Due to the anonymous nature of the research, it was not possible for 
the author to make direct contact with participants in the event of concern, and this 
was outlined clearly in the consent form.  
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4.2 Psychometric Properties of Measures Used 
4.2.1 Insulin Measure. Psychometric information for this measure is in 
development. Full details of this measure can be seen in Appendix G. 
4.2.2 The Eating Disorder Examination-Questionnaire. A review of the 
psychometric properties of the EDE-Q (Berg, Peterson, Frazier, & Crow, 2012) 
indicated that test-retest reliability ranges from 0.66 to 0.94 for subscale scores, with 
acceptable internal consistency (Cronbach’s a:  0.70 to 0.93). In this study, 
Cronbach’s a was .94. Full details of this measure can be seen in Appendix H. 
4.2.3 Body Shape Questionnaire (BSQ). Acceptable test-retest reliability 
(.88) was reported, along with good concurrent validity (Rosen, Jones, Ramirez, & 
Waxman, 1996). In this study, Cronbach’s a was .98. The lead author, Dr Melanie 
Bash (nee Taylor) gave permission for the wording of the questionnaire to be altered 
to use gender-neutral terms (M. Bash, personal communication, May 16, 2017). Full 
details of this measure can be seen in Appendix I. 
4.2.4 Diabetes Distress Scale (DDS). Internal consistency for the whole 
scale is excellent (Cronbach’s a:  0.93), and good for the subscales (Cronbach’s a:  
0.88 – 0.9). The scale has good validity (Polonsky et al., 2005). In this study, 
Cronbach’s a was .95. Full details of this measure can be seen in Appendix J. 
4.3 Adjustments to Insulin Measure 
The insulin measure designed by Ames (2017) was initially developed as a 
quantitative measure, with options for participants to include narrative responses. 
Participants provided qualitative information on the reasons that they did not take 
insulin as prescribed. This information was analysed using a thematic analysis 
approach and five themes were extracted: “a) Prioritising: forgetting and the 
demands of daily lifestyle, b) Diabetes related emotional distress, c) Weight control, 
 93 
d) Avoidance: Fear of physical effects, and e) Adaptive responses to managing blood 
sugar levels” (Ames, 2017). With the author’s approval (S. Ames, personal 
communication, April 2017), and based on these themes, the questions were 
transformed into quantitative questions for this study, using the above themes as 
multiple-choice options. “Weight Control” was split into “Weight Control” and 
“Weight Loss” to better capture the specifics of this behaviour. An “Other” option 
was added to allow for reasons that were not included in the multiple-choice options, 
where qualitative information could be provided by participants. Given that the 
changes made to the scale were minor and were made based on the findings of the 
thematic analysis carried out by the author (Ames, 2017), pilot testing of the 
adjustment was not considered necessary.  
4.4 Extended Procedure 
As described in the empirical paper above, a cross-sectional design using 
self-report questionnaires was used. Several advantages were afforded by this 
design, including the level of anonymity offered, which has been found to reduce 
levels of bias when reporting sensitive personal information (Schroder, Carey, & 
Vanable, 2003), and the generalisability of results and ease of data collection 
(Sturgis, 2006). In diabetes specifically, the accuracy of self-report has been found to 
be good (Huerta, Tormo, Egea-Caparrós, Ortolá-Devesa & Navarro, 2009). The 
presence of depressive symptoms has been identified as a predictor of accurate 
reporting in a diabetic population (Molenaar, Ameijden, Grobbee & Numans, 2006). 
Similarly, people with eating disorders self-report weight very accurately, on 
average (McCabe, McFarlane, Polivy & Olmsted, 2001). Thus, it is reasonable to 
expect that self-reporting would yield accurate results in this population. There were, 
however, some disadvantages to this method. There was a risk of a biased sample, as 
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this method only captured responses from those who have the means and interest to 
engage with online support communities.  
Following ethical approval, the gatekeepers for online support communities, 
including diabetes.co.uk, diabetes.org.uk, Diabetics with Eating Disorders (DWED), 
Beat and JDRF (formerly known as Juvenile Diabetes Research Foundation) were 
initially approached by email. They were asked for permission to post information 
about the proposed study on their web forums, social media pages and online 
newsletters. JDRF declined to be involved and numerous attempts to make contact 
with both Beat and diabetes.co.uk yielded no response. Diabetes.org.uk and DWED 
both agreed to facilitate recruitment by posting details of the study online. Following 
discussion, details regarding the study and requests for participants were posted in 
the agreed locations. 
In addition, a Twitter account was created for the study, as a strong online 
diabetes community was identified. Adverts for the study were posted on a frequent 
basis to Twitter using “hashtags” to widen the reach of the post. These posts were 
often “retweeted” by prominent members of the online diabetes community on an 
entirely voluntary basis. Approximately 230 retweets of the original tweets were 
recorded. The UEA email address of the author was provided to allow potential 
participants to get in touch with any questions, comments or concerns they may have 
had during the study. 
The survey was hosted on Online Surveys (https://www.onlinesurveys.ac.uk) 
via a dedicated account for the study. Participants first read an information page 
regarding the study, consent, and their right to discontinue at any time (Appendix D). 
If they wished to continue, they read further statements regarding consent and were 
asked to indicate their consent to continue by selecting an option (Appendix E).  
 95 
It was estimated that the survey would take no longer than 30 minutes to 
complete. Participants completed the measures outlined above, which were presented 
as follows: demographics; insulin measure; EDE-Q; BSQ; Diabetes Distress Scale. 
The decision was made to order the measures in this manner as a degree of 
discontinuation was expected, and it was hoped that this order would allow the 
maximum number of responses to the insulin questionnaire. However, Online 
Surveys does not currently have the facility to download incomplete datasets, and so 
only complete datasets were included in the final analysis.  
4.5 Data Preparation and Screening 
4.5.1 Assumption of Normality. The survey was conducted online, and the 
software used generated results that could be directly imported into SPSS, reducing 
the chance of errors in data entry. Nonetheless, the data were manually screened for 
errors, such as numbers that were outside the range of possible scores. No errors 
were identified.  
 The results for the continuous measures were assessed for normality. 
However, given the large sample size (N = 219), many standard indicators of 
normality (e.g. values of skewness and kurtosis) are not recommended for use as 
they will pick up on even minor deviations (Field, 2009). The Kolmogorov-Smirnov 
and Shapiro-Wilk tests both indicated a significant deviation from normality for all 
measures. Given that these tests are also sensitive to sample size, histograms were 
used to assist in the interpretation of normality. These suggested that the data were 
non-normal.  
 Consideration was given to using non-parametric test alternatives, which do 
not require a normal distribution. Nonparametric tests are less sensitive than 
parametric tests, however, and may fail to detect differences between groups that 
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parametric tests would pick up (Pallant, 2013). The decision on whether it is 
appropriate to use parametric or non-parametric analyses is a controversial one in the 
health sciences (Norman, 2010). The violation of the assumption of normality is a 
frequently cited reason as to why parametric statistics are not appropriate. Norman 
(2010) cites research dating back to 1931 that indicates that parametric analyses such 
as t-tests and ANOVA are robust to violations of normality. Furthermore, Lumley, 
Diehr, Emerson and Chen (2002) ran a number of simulations and concluded that 
parametric statistics such as t-tests are perfectly valid for non-normal data, given a 
large enough sample size (the authors did not specify what “large enough” is, but 
suggested that it would apply to sample sizes greater than 100). Having considered 
the literature, and in consultation with the programme’s Statistics Tutor, the decision 
was made to proceed with parametric analyses, given the large sample size.  
4.5.2 Outliers. At times, outliers in the data were detected. Given the method 
of data collection, along with prior manual screening, these outliers were not a result 
of data entry or measurement errors, which suggests that they reflected genuinely 
unusual scores. There are a number of options available to deal with outliers, 
including removing the problematic cases, transforming the data or changing the 
score (Field, 2009). Removing a case from an analysis because it is an outlier is a 
controversial approach that is only recommended in the event that there is strong 
evidence to suggest that the case does not belong to the population being targeted 
(Field, 2009). In this study, there was no identifiable evidence to suggest that this 
was the case.  
 It is possible to transform data in the event that data are also non-normal. 
However, transformation must be applied to all variables when they are to be used in 
an analysis (Field, 2009) and the type of transformation that is appropriate depends 
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on the skew of the data. The type of skew might differ between variables and 
transforming data might be successful for one particular variable but may negatively 
impact another variable in the analysis (Field, 2009). Finally, Field (2009) suggests 
that, in the event that transformation fails, the scores can be changed using a number 
of mathematical approaches.  
 After considering the available options, the decision was made to present the 
data as-is, without any transformations or adaptations for outliers. This facilitates a 
more honest description of the results and avoids highlighting any individual 
responses as ‘problematic’.  
4.6 Power Analyses 
 Calculating the power of statistical tests helps to avoid Type II errors (i.e. 
false negatives; Clark-Carter, 2010). A generally accepted power value is .8 (Clark-
Carter, 2010) and this value can be used prospectively in conjunction with effect size 
(d) to determine appropriate sample sizes that are required to achieve the given level 
of power. As mentioned in the empirical paper, a medium effect size (.5) was used to 
calculate sample sizes, based on previous research (Ames, 2017) and discussion with 
the UEA Statistics Tutor. Power tables provided by Clark-Carter (2010) and 
G*Power version 3.1 were used for these calculations.  
4.6.1 Chi-squared. Power analysis for a chi-squared test (df = 1) was 
conducted to determine a sufficient sample size using an alpha of .05, a power of .80 
and a medium effect size (d = .5). Based on these assumptions, a total sample size of 
32 was required. 
4.6.2 Logistic Regression. Power analysis for a logistic regression was 
conducted to determine a sufficient sample size using an alpha of 0.05, a power of 
0.80, an odds ratio of 1.5 and two-tailed test. Based on the aforementioned 
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assumptions, the desired sample size was 208. Guidance for this analysis was 
provided by Faul, Erdfelder, Lang and Buchner (2007) and Faul, Erdfelder, Buchner 
and Lang (2009).  
4.6.3 t-tests. Power analysis for a two-tailed between-groups t-test was 
conducted to determine a sufficient sample size using an alpha of .05, a power of .80 
and a medium effect size (d = .5). Based on these assumptions, a total sample size of 
128 participants is required, or 64 per group.  
4.6.4 One-way multivariate analysis of variance (MANOVA). Power 
analysis for a MANOVA with three levels and three dependent variables was 
conducted to determine a sufficient sample size using an alpha of .05, a power of .8. 
and a medium effect size (f2(V) = .0625). Based on these assumptions, a total 
sample size of 114 was required.  
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This chapter elaborates on some of the findings from the empirical paper and 
provides details of further analyses that could not be included in the empirical paper 
due to a word count limit set by the chosen journal.  
5.1 Discontinuations 
 Seventy-seven people discontinued the survey without finishing. Of these, 
three did so during the demographics section, 34 did so during the Insulin Measure, 
31 did so during the EDEQ, 5 during the BSQ and 4 during the DDS. It must be 
noted that the study design allowed for participants to take a break from completing 
the survey and to return to it later. It is possible that people may have paused and 
intended to return, but either forgot or did so after the survey had been closed to 
further respondents. The curve was generally bell-shaped, indicating a normal 
distribution of discontinuations. 
5.2 Insulin Measure 
5.2.1 Characteristics of doses likely to be omitted. Of those who provided 
qualitative information about whether there is a particular insulin dose that they are 
likely to omit (N = 213), 117 (55%) replied that they do not omit a particular dose 
(or do not omit at all). Thirty-three people (15%) identified a period from ‘evening’ 
to ‘night’, including around dinner time, as the time that they’re likely to omit, 12 
people (6%) endorsed omitting in the morning and another 12 people reported 
lunchtime as the most frequent time they omit a dose. Other occasions that were 
described including during work times, prior to exercise, when the person had been 
snacking and when they were in the presence of other people.  
5.2.2 Associations with Mood. When asked if their mood affected their 
likelihood of taking insulin as prescribed, 99 (46%) people responded that it did not. 
Another 102 people (48%) agreed that their mood impacted their insulin adherence, 
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with low mood specified by 21 people as a reason and 11 people specifying 
frustration with diabetes as a reason. With regard to whether taking insulin affects 
their mood, 114 people (53%) of people denied this, while 79 people (37%) were 
clear that taking insulin impacts their mood. The remainder of the responses were 
unsure about the relationship between insulin and their mood. Some illustrative 
responses provided are described in Table 5.1. These responses indicate that the 
relationship between mood and insulin is a complex and personal one, with many 
factors that may have an impact.  
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Table 5.1 
Select responses regarding the association between insulin and mood 
Question Sample Responses (Direct quotations) 
Does your 
mood affect 
how you take 
insulin? 
“Yes, low mood affects my level of attention/willingness to deal with my 
condition.” 
“Occasionally, yes. More often than not it is apathy and ignorance as well as 
frustration about my diabetes that would affect how I take insulin” 
“Yes because I sometimes hate having diabetes and the way other people have 
made me feel about it can make me feel very self conscious” 
“Yes, when feeling negative it becomes overwhelming having to calculate carbs 
and having fear of hypos” 
“yes, bad/low/depressed mood stops me jabbing, as I don't see the point and when 
i feel and look fat.” 
“Yes, depression happens then less inclined to take insulin, whereas mh team 
think not taking insulin is cause of my depression” 
“Yes even though i know i have to take it and what happens when i dont if im in a 
bad mood i dont take it either because i go into denial or i just dont care” 
 
Does taking 
insulin affect 
your mood? 
“Yes - it feels like such a burden and I am petrified of complications” 
“Yes - sometimes I feel frustrated by the inconvenience of it, especially if I am 
stressed or pushed for time.” 
“Yes, usually makes me feel better when levels get in range.” 
“Yes, I feel worse mentally when I’ve taken it almost as if I’ve given in or 
cheated” 
“Yes, I think when taking it regularly I feel slightly more upbeat” 
“I feel better when I do but I still resent it” 
“Yes, I feel happier when I take insulin and feel well, but anxious when I take it 
that I’ll put on weight” 
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5.3 Predictive Analysis 
Further details of this analysis are provided below, as this information could 
not be included in the Empirical Paper due to journal restrictions.  
Given the categorical nature of the dependent variable (insulin misuse), a 
binomial logistical regression was appropriate. The Box-Tidwell (1962) procedure 
was used to assess the linearity of the continuous variables (EDEQ, BSQ and DDS 
scores) with respect to the logit of the dependent variable. As is recommended when 
multiple comparisons are being performed (Tabachnick & Fidell, 2007), a 
Bonferroni correction was applied for the eight terms in the model, resulting in a 
statistical significance threshold of p < .00625 being applied. As a result of this, the 
continuous independent variables were confirmed as linearly related to the logit of 
the dependent variable.  
When testing for outliers, Field (2009) suggests that Standardised Residual 
values above 3 should be inspected more closely as they may represent outliers in 
the data. Four values exceeding 3 were identified and each dataset was examined 
individually. Each respondent denied purposefully misusing insulin. No datasets 
were removed from the analysis following this investigation.   
The results of the model are described in detail in Chapter Three. However, 
to investigate if the results of this model would differ between males and females, 
the dataset was split and the analysis was repeated as above, with gender removed as 
a predictor variable.  
5.3.1 Males. The model was statistically significant, c2(3) = 14.154, p = 
.003. It explained 35% (Nagelkerke R2) of the variance in insulin misuse and 
correctly classified 76.6% of cases. Specificity was 81.8% and sensitivity was 72%. 
The positive predictive value was 81.82% and the negative predictive value was 
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72%. However, none of the variables were significant predictors of insulin misuse in 
males. See Table 5.2 for full details.  
5.3.2 Females. The model was again found to be statistically significant, 
c2(3) = 34.321, p < .0005. It explained 26% (Nagelkerke R2) of the variance in 
insulin misuse and correctly classified 77.2% of cases. Specificity was 42.9% and 
sensitivity was 91%. The positive predictive value was 79.9% and the negative 
predictive value was 65.6%. Again, neither EDEQ nor BSQ were predictors of the 
likelihood of insulin misuse in women, with diabetes-related distress acting as a 
significant predictor. See Table 5.3 for full details.  
Table 5.2 
Logistic Regression Predicting Likelihood of Insulin Misuse in Males 
 B SE Wald df p Odds 
Ratio 
95% CI for Odds 
Ratio 
 Lower Upper 
EDEQ -.983 .747 1.732 1 .188 .374 .087 1.617 
BSQ 0.58 .033 3.109 1 .078 1.060 .994 1.130 
DDS .708 .404 3.065 1 0.80 2.029 .919 4.483 
Constant -3.731 1.402 7.087 1 0.008 .024   
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Table 5.3 
Logistic Regression Predicting Likelihood of Insulin Misuse in Females 
 B SE Wald df p Odds 
Ratio 
95% CI for Odds 
Ratio 
 Lower Upper 
EDEQ -.348 .295 1.396 1 .237 .706 .396 1.258 
BSQ 0..9 .009 1.086 1 .297 1.009 .992 1.026 
DDS .933 .220 18.034 1 .000 2.541 1.652 3.909 
Constant -1.951 .583 11.219 1 .001 .142   
 
5.4 One-way multivariate analysis of variance (MANOVA) 
 Again, this section provides further details of this analysis that were not 
included in the Empirical Paper due to journal restrictions.  
To investigate differences between those who do not misuse insulin, those 
who misuse for weight purposes and those who misuse for other reasons on scores of 
the EQEQ, BSQ and DDS respectively, a MANOVA was performed. The data were 
coded into groups depending on misuse. When a participant indicated that they 
misuse insulin for weight purposes, they were coded into that group regardless of 
any other reasons they may have provided for misusing insulin. Data are expressed 
as mean ± standard deviation.  
 When testing the assumptions of a MANOVA, a small number of univariate 
and multivariate outliers were identified by inspection of a boxplot. The datasets 
were further inspected, and the decision was made to include them in the analysis, as 
they appeared to reflect genuinely unusual values as opposed to an error. Violations 
of the assumptions of normality were found. However, a MANOVA is considered 
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quite robust to a violation of this assumption (Laerd Statistics, 2015) so the decision 
was made to proceed without transforming or otherwise manipulating the data. For 
further information on this decision, see the Data Preparation and Screening section 
(93). Pearson correlation was used to screen for multicollinearity, and none was 
detected. Linear relationships were confirmed between the variables, as assessed by 
scatterplots. Box's test of equality of covariance matrices confirmed homogeneity of 
variance-covariances matrices (p = .310). 
 People who misuse insulin for weight purposes scored more highly on all 
three measures (3.12 ± 1.11, 140.97 ± 42.53, 4.22 ± 1.14, respectively) than both the 
other insulin misuse group (1.63 ± 1.18, 91.00 ± 43.84. 3.14 ± 1.10) and the group 
who did not misuse insulin (1.29 ± 1.04, 70.50 ± 35.75, 2.18 ± 1.09).  
 The differences between the groups on the combined dependent variables 
was statistically significant F(6, 430) = 16.255, p < .0005, Pillai’s Trace = .370, 
partial η2 = .185. Given the unequal sample sizes between the groups, Pillai’s Trace 
was used in preference to Wilks’ Lambda.  
 Post-hoc tests were carried out to determine whether the variables were 
contributing in a statistically significant manner to the model. Each variable 
appeared to be acting in this manner. There was a statistically significant difference 
on EDEQ scores between all three insulin misuse groups, F(2, 216) = 30.759, p < 
.0005, partial η2 = .222. There was also a statistically significant difference on BSQ 
scores, F(2, 216) = 32.638, p < .0005, partial η2 = .232, and on DDS scores, F(2, 
216) = 40.313, p < .0005, partial η2 = .272. As there are three dependent variables in 
the model, the level of significance was adjusted to .017 using a Bonferroni 
correction.  
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 As discussed previously, Tukey HSD post-hoc analyses indicated those who 
misuse insulin for weight purposes had significantly higher mean scores on the 
EDEQ than those who do not misuse insulin at all (p < .0005) and those who misuse 
insulin for non-weight reasons (p < .0005). However, EDEQ mean scores were not 
statistically significantly different between those who misuse insulin for non-weight 
purposes and those who do not misuse insulin (p = .119). There was a statistically 
significant difference between all groups for scores on the BSQ and DDS measures 
(p < .01).  
5.5 Exploratory Analyses 
Given that previously published research has tended to focus on the 
experience of females with type 1 diabetes, it would be beneficial to further explore 
the experiences and perceptions of males with type 1 diabetes. In this study, only 47 
males with type 1 diabetes were recruited, despite a broad recruitment strategy. 
Between-gender analyses may be useful to guide future research, but the number of 
male datasets available for this study precluded adequately powered between-groups 
analyses being carried out, as a minimum of 64 per group is suggested (see Extended 
Methodology section for further details). Nonetheless, useful information may be 
gathered despite the limitation of being under-powered, with the understanding that 
the results presented below are intended only to guide future research and are 
intended to be interpreted with significant caution.  
5.5.1 Scores on Individual Measures. The group scores on the individual 
measures are reported in Table 5.4.  
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Table 5.4 
Mean Group Scores on Measures (N = 219) 
Measure M SD 95% CI for Mean 
 Lower Upper 
EDEQ Total 1.78 1.27 1.58 1.92 
EDEQ Restraint 1.77 1.60 1.56 1.99 
EDEQ Eating Concern 1.27 1.43 1.08 1.46 
EDEQ Shape Concern 2.15 1.44 1.95 2.34 
EDEQ Weight Concern 1.80 1.29 1.63 1.98 
BSQ Total 92.07 46.87 85.83 98.32 
DDQ Total 2.99 1.29 2.83 3.17 
DDS Emotional Burden 3.51 1.55 3.31 3.72 
DDS Physician-Related 
Distress 
2.57 1.53 2.37 2.78 
DDS Regimen-Related 
Distress 
2.91 1.49 2.71 3.10 
DDS Interpersonal Distress 2.87 1.51 2.67 3.07 
 
5.5.2 EDEQ. Norms have typically been calculated for the EDEQ using 
female samples (e.g. Fairburn & Beglin, 1994; Mond, Hay, Rodgers & Owen, 2006), 
and limited data is available for norms for combined genders. To compare group 
scores in this study with published norms, the dataset was split by gender and two-
tailed independent samples t-tests were conducted to compare whether significant 
differences in scores were reported between the current group with type 1 diabetes 
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and norms established by gender for US college students (Quick & Byrd-
Bredbenner, 2013). Results can be seen in Tables 5.5 and 5.6.  
Table 5.5 
Comparison between mean EDEQ scores for males in the current group compared 
to norms* 
Scale M SD M SD t p 
 Type 1 Diabetes (N = 47) Normed Sample* (N = 915) 
EDEQ Restraint 1.17 1.29 0.96 1.28 1.12 .26 
EDEQ Eating Concern 0.600 0.90 0.40 0.71 1.86 .06 
EDEQ Shape Concern 1.37 1.29 1.36 1.36 0.05 .96 
EDEQ Weight Concern 1.14 1.04 1.07 1.18 0.39 .69 
EDEQ Total 1.07 0.99 0.95 .98 0.82 .41 
Note. df = 960. *Norms obtained from Quick & Byrd-Bredbenner (2013) 
 
Table 5.6 
Comparison between mean EDEQ scores for females in the current group compared 
to norms* 
Scale M SD M SD t p 
 Type 1 Diabetes (N = 171) Normed Sample* (N = 1,533) 
EDEQ Restraint 1.94 1.65 1.35 1.43 5.04 < .0001 
EDEQ Eating Concern 1.46 1.50 0.89 1.09 6.22 < .0001 
EDEQ Shape Concern 2.36 1.41 2.39 1.63 0.23 .82 
EDEQ Weight Concern 2.00 1.30 1.98 1.60 0.16 .88 
EDEQ Total 1.94 1.28 1.65 1.30 2.77 .0056 
Note. df = 1702. *Norms obtained from Quick & Byrd-Bredbenner (2013) 
No significant differences are seen on EDEQ scores between males with type 
1 diabetes and a non-clinical sample of US college-age males. For females, 
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significant differences are seen between the type 1 diabetes population and a non-
clinical sample of US college-age females for Restraint, Eating Concern and the 
Total score. When a Bonferroni correction was applied for the five items in the 
analysis, a significance level of .01 was required. The differences between groups 
remained statistically significantly different. However, the differences are non-
significant on the Shape and Weight subscales, which may suggest that the 
differences could be related to the pressures of maintaining a healthy diet that come 
with type 1 diabetes as opposed to eating disorder psychopathology.  
As the EDEQ is not designed with a clinical “cut-off” score, it is not possible 
to determine how many individuals may have indicated clinically concerning scores.  
5.5.3 BSQ. The author of the BSQ suggests that a score of < 80 suggests no 
concern with body shape, while a score of 80 – 110 suggests “mild concern”. 
Overall, the group scored in the “mild concern” range; however, differences were 
seen when the data were separated by gender. An independent t-test was performed 
to investigate differences between males (M = 58.36; SD = 27.34) and females (M = 
101.56; SD = 46.92) with type 1 diabetes on the BSQ, which found that females 
scored statistically significantly higher than males, t(127.935) = 8.051, p < .0001 
(assuming unequal variances). These results suggest that males with type 1 diabetes 
do not report body shape concern, while women report “mild concern”. It must be 
noted that the wording of the BSQ does tend to align with female body shape 
concerns more than male concerns, so this result must be interpreted with caution.  
 Individually, seven males (15%) and 30 females (17.5%) scored within the 
“mild concern” range of the BSQ, and three men (6%) and 29 women (17%) scored 
within the “moderate concern” of 111 to 140. No males, but 43 females (25%), 
scored in the “marked concern with shape” range, requiring a score of 140 or higher. 
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5.5.4 DDS. Significant differences were seen between males and females for 
diabetes-related distress, with women reporting greater degrees of distress. The 
results of the between-groups t-test are reported in Table 5.7.  
Table 5.7 
Differences between males and females on DDS scores 
 M SD M SD t p 
 Males (N = 47) Females (N = 171) 
DDS Total 2.47 1.30 3.14 1.25 -3.199 .002 
DDS Emotional Burden 2.91 1.62 3.67 1.49 -3.045 .003 
DDS Physician-Related Distress 2.15 1.54 2.68 1.51 -2.089 .038 
DDS Regimen-Related Distress 2.40 1.41 3.04 1.49 -2.620 .009 
DDS Interpersonal Distress 2.29 1.55 3.03 1.46 -3.038 .003 
Note. df = 216 (equal variances assumed).  
Significant differences were seen on total score and all subscales. When a 
Bonferroni correction was applied for the five items in the analysis, a significance 
level of .01 was required, and a significant difference was no longer observed 
between groups for physician-related distress. The authors of the DDS suggest that a 
score of 3 or higher suggests a clinical level of distress (Polonsky et al., 2005). 
Clinical distress levels were not observed in mean scores for male participants, but 
the mean score for females was above 3 on all subscales, with the exception of 
physician-related distress.  
Individually, 16 males (34%) and 91 females (53%) scored 3 or higher on the 
DDS total scale. Nineteen males (40%) and 109 females (64%) scored 3 or higher on 
the Emotional Burden subscale; 11 males (23%) and 72 females (42%) scored 3 or 
higher on the Physician-Related Distress subscale; 14 males (30%) and 86 females 
(50%) scored 3 or higher on the Regimen-Related Distress subscale; and nine males 
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(19%) and 85 females (50%) scored 3 or higher on the Interpersonal Distress 
subscale.  
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This chapter will provide an overview of the whole thesis portfolio, including 
summary and discussion of the main findings reported, along with additional 
findings reported in the extended methodology and results chapters. It will provide 
links between these findings and previous literature, as well as critically appraising 
the strengths and limitations of this portfolio. Finally, clinical and theoretical 
implications of this research will be discussed, along with suggestions for future 
research.  
6.1 Research Aims 
This portfolio aimed to investigate insulin misuse in people with type 1 
diabetes, with particular reference to the relationship between insulin misuse and 
eating disorder psychopathology, and the impact of diabetes-related distress. The 
systematic review aimed to address a gap identified in the literature with regard to 
the experiences of men with type 1 diabetes in relation to insulin misuse for the 
purposes of weight control or loss. It aimed to investigate whether men reported this 
behaviour, and the prevalence rates of the behaviour. The empirical paper aimed to 
explore insulin misuse amongst adults with type 1 diabetes in more detail, 
specifically exploring the rates of insulin misuse reported, the relationships between 
insulin misuse and eating disorder psychopathology, perception of body shape and 
diabetes-related distress, and whether gender differences existed.  
6.2 Summary of Main Findings 
The systematic review indicated that men do report insulin misuse for the 
purposes of weight loss or control. However, prevalence rates could not be 
determined due to the heterogeneity between the included studies. It was noted that 
men did not report insulin misuse for weight purposes when assessed via the use of a 
semi-structured interview, but varying rates were reported via self-report 
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questionnaires. A lack of standardised measure for insulin misuse was highlighted as 
a reason for difficulty in comparing between studies, as this meant that significantly 
different approaches were used between studies to operationalise the behaviour.  
The empirical paper established that a significant proportion of respondents 
reported insulin misuse, with fewer than 35% of participants reporting adhering 
correctly to their insulin regime. Women were more likely to misuse insulin than 
men, both for weight control purposes and in general. Insulin misuse for weight 
purposes was common amongst participants with a current or historical diagnosis of 
an eating disorder (56%), but just over 6% of participants with no history of an 
eating disorder reported engaging in this behaviour. Significantly higher levels of 
disordered eating behaviours were seen amongst people who misused insulin than 
those who didn’t report insulin misuse, along with significantly worse perceptions of 
their body shape and higher levels of diabetes-related distress. Regimen-related 
distress emerged as a particularly strong issue amongst people who misused insulin.  
A logistic regression was carried out to understand whether and how the 
variables act together to affect insulin misuse. Including EDEQ scores, BSQ scores, 
DDS scores and gender in the model explained 29.1% of the variance, but the only 
significant predictor identified was diabetes-related distress, with greater levels of 
diabetes-related distress associated with higher likelihood of insulin misuse. 
A MANOVA allowed the opportunity to investigate between insulin misuse 
groups. Three groups were identified, namely those who misused insulin for weight 
purposes, those who misused for other reasons but did not endorse misusing for 
weight, and those who denied misuse. As would be expected, the misuse for weight 
group scored significantly more highly than the other groups on the EDEQ and BSQ, 
but also significantly more highly on DDS. All three groups had scores that were 
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statistically significantly different from each other on the BSQ and DDS, while the 
misuse for weight group had significantly higher scores on the EDEQ than the other 
two groups, who did not differ significantly between each other on the EDEQ.  
Overall, the most common reason for insulin omission reported by both men 
and women was that something else took priority at the time, followed by negative 
feelings about diabetes. However, taking an incorrect dose was most commonly done 
for either reasons of avoidance or fear of physical effects, or for planning around the 
potential for hypoglycaemia.  
The findings gave support to the hypothesis that insulin misuse for weight 
purposes may not be a symptom of eating disorders as currently recognised by the 
DSM-5 but may be better understood as a distinct construct that deserves individual 
attention in order to inform and improve treatment outcomes.  
6.3 Summary of Additional Findings 
In general, no strong pattern was identified with regard to the characteristics 
of specific insulin doses that were likely to be omitted. Of those who felt there was a 
pattern to their omission, the evening or night-time dose appeared to be the most 
frequently omitted. This may be worth further investigation as the long period 
between dinner and breakfast may increase the risk of hyperglycaemia occurring 
while sleeping. Hyperglycaemia may negatively affect sleep by increasing the 
frequency of urination, and poor sleep may make it harder to closely monitor 
glycaemic control the following day. This has the potential to cause a vicious cycle 
for people with type 1 diabetes that makes it harder to regain good glycaemic 
control.  
The sample was split evenly in perception of whether there was an 
association between insulin and mood. The dichotomy was striking, given that the 
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majority (53%) denied an association, but those that identified an association felt 
quite strongly about the link. One participant even commented “This is a daft 
question… Of course [taking insulin] does [affect my mood]”. Low mood and 
frustration with diabetes were identified as reasons for difficulty with correct 
adherence.  
Further exploration through logistic regression, with gender removed as a 
variable and the dataset instead split by gender, indicated that the model explained 
35% of the variance for males but none of the variables were significant predictors 
of insulin misuse. In females, the model explained 26% of the variance with 
diabetes-related distress again acting as the only significant predictor of insulin 
misuse. It must be noted that the small male sample size inhibits interpretation of the 
findings, as females may mask males in the overall model.  
Finally, tentative exploratory analyses were carried out with the aim of 
guiding future research. These analyses suggested that males with type 1 diabetes did 
not differ from a non-clinical sample on EDEQ scores, while females with type 1 
diabetes differed significantly from a non-clinical female sample for subscales 
related to eating, but not to weight and shape, which may be consistent with the 
demand of managing diabetes. Women with type 1 diabetes also scored significantly 
more highly than men with type 1 diabetes on the BSQ, but this may be influenced 
by the wording of the questions, which over-represent female shape concerns 
compared to males. Females also scored significantly more highly than males on the 
DDS, but again this must be interpreted with caution due to the underpowered nature 
of the analyses on the male group.  
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6.4 Strengths and Limitations 
This portfolio has a number of strengths. Type 1 diabetes is relatively under-
investigated compared to type 2 diabetes. This may be influenced by the relative 
numbers of people affected by each condition, with only 10% of people with 
diabetes having type 1. However, type 2 diabetes has the potential to be controlled or 
even reversed through lifestyle adjustments, while type 1 diabetes is a chronic 
disorder that cannot be cured at this time. Thus, an argument could be made that the 
psychological impact of type 1 diabetes is potentially greater than that of type 2 
diabetes and is an area deserving of more attention in the research literature. This 
study provides an insight into the experiences of people with type 1 diabetes 
exclusively, avoiding the common approach in the literature of combining the two 
conditions and potentially masking the subtleties and nuances of living with type 1 
diabetes.  
The systematic review was the review was the first of its kind to focus on the 
experiences of males with type 1 diabetes with regard to insulin misuse for weight 
purposes. Previous studies in this area have focused on the experiences of females 
which has resulted in a poor understanding of insulin misuse and weight control in 
males. According to the Hierarchy of Evidence, a systematic review is generally 
considered to provide an excellent level of evidence which provides a strong 
scientific base for informing clinical practice (Evans, 2003). Carrying out this review 
allowed for the conclusion to be drawn with reasonable certainty that men do report 
misuse insulin for the purposes of weight loss or control, and this finding can inform 
clinical practice.  
The empirical study was well-received by the type 1 diabetes community. A 
good sample size was gathered, allowing for statistically powered analyses to be 
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undertaken. Some feedback from participants included comments such as “some 
issues very close to home here, which nobody speaks about so well done for reaching 
out to ask some rather taboo questions”, “Going through anxiety / depression issues 
so the not taking my insulin part fitted in nicely with this questionnaire” and “It’s an 
interesting side to [type 1 diabetes]... my diet is stupid just to keep my sugars 
normal, (and therefore my weight is low) but obviously the other way - high sugars 
and no food, is so much worse”.  
Recruiting through online support communities allowed direct contact with 
potential participants, while maintaining confidentiality and anonymity in 
responding, and recruitment was bolstered by high-profile members of the 
community endorsing participation in the study. It was hypothesised that self-report 
measures may yield a more accurate representation of the prevalence of insulin 
misuse, and the results are in line with findings in other research that used self-report 
measures (e.g. d’Emden et al., 2013; Neumark-Sztainer, 2002). The insulin measure 
used (Ames, 2017) was developed in collaboration with healthcare professionals and 
service users, allowing for a robust investigation into the reasons and frequency of 
insulin misuse based on both previous research and stakeholder input.  
However, in common with most studies in this field, there were some 
limitations. Heterogeneity across studies included in the systematic review precluded 
the estimation of prevalence rates for insulin misuse in males for weight purposes, 
nor could the studies be directly compared statistically.  Another limitation was that 
planning for the empirical study took place prior to completing the systematic 
review. The results of the systematic review lent themselves to further research and 
an emphasis may have been put on recruiting more male respondents had these been 
known at an earlier stage.  
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The measures used to assess eating disorder psychopathology were limited 
due to their female focus and lack of adaptation for a diabetes sample. The EDEQ 
was included on the basis of it being considered to be the gold standard self-report 
assessment tool for eating disorders; however, it may have been more suitable to use 
a measure such as the Diabetes Eating Problem Survey Revised (DEPS-R; Antisdel, 
Laffel & Anderson, 2001) which is specific to type 1 diabetes and includes a 
consideration of insulin misuse for weight purposes as a type of disordered eating 
behaviour. It is a 16-item measure with excellent internal consistency (Cronbach’s a 
= 0.86), construct validity and external validity (Markowitz et al., 2010). However, 
internal validity has been found to be weaker for males than females (Cronbach’s a 
= 0.81 and 0.90, respectively), and it is a brief screening tool that explores 
behaviours in less depth than the EDEQ (Wisting, Frøisland, Skrivarhaug, Dahl-
Jørgensen & Rø, 2013). 
The BSQ was adapted with permission to use gender-neutral terms (the 
original refers specifically to “other women”), but it transpired that the questions 
were still quite specific to female concerns, and not representative of the range of 
shape concerns that may be present in both genders. This was highlighted in 
feedback from some participants. One female participant noted “I did find the 
questions a bit hard to answer, because there weren't any options for wanting to lose 
weight, or being bothered about body shape, because of the fear of carrying too 
much visceral fat (having a thick waistline) which is what worries me if I put on a 
few pounds. All the questions that touched on body shape were whether you had a 
problem with what your bottom and thighs were like, which I don't have a problem 
with, but then it made my answers to some of the other questions look a bit strange.”, 
while an email received from a male participant stated “a lot of the questions seemed 
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geared to people feeling as though they are too large or too fat. I don't have that 
worry and, in my experience not too many people with type 1 diabetes do. Rather it's 
the opposite, I am very thin, and male, and fit more closely into the '9 stone 
weakling' or 'mr muscle' body shape than the muscular and brawny shape which is 
stereotypically seen as attractive or something to strive for among men”. 
This connects with a general limitation of research regarding eating disorders 
in males, as there are currently no known measures of eating disorder 
psychopathology specific to males, and none specific to men with type 1 diabetes. A 
further limitation was the lack of depth and detail that could be captured by self-
report questionnaires.  
Finally, the recruitment strategy for the empirical study had several 
advantages, as outlined above, but also had disadvantages. Recruitment was broadly 
restricted to those who engage with online support communities, which risked 
missing a subsection of the population who do not routinely engage with the diabetes 
community online. A selection bias may have been at play, with those motivated to 
complete the survey potentially being more likely to seek support overall and to be 
open about difficulties in managing type 1 diabetes (Greene, Choudhry, Kilabuk & 
Shrank, 2011). This may have yielded over-inflated scores on the Diabetes Distress 
Scale and failed to capture the perspectives of those who feel they are managing 
their diabetes successfully. Similarly, without a biological measure of glycaemic 
control, a potential for over- or under-reporting of insulin misuse could not be 
controlled for. However, research suggests that self-report regarding medication 
adherence correlates reasonably well with other measures of adherence and can 
significantly predict clinical outcomes (Stirratt et al, 2015).  
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6.5 Theoretical Implications 
 The systematic review confirms that insulin misuse for weight purposes is 
reported in men with type 1 diabetes, albeit with currently unclear prevalence rates. 
This has previously been dismissed by researchers who have failed to find evidence 
of the behaviour in individual studies (e.g. Fairburn et al, 1991). In the present study, 
three men (6.4%) reported omitting insulin for weight loss or control and the same 
proportion reported taking an incorrect dosage for this purpose. The findings lend 
support to the hypothesis that men are more likely to report engaging in this 
behaviour when given the opportunity to respond through a self-report measure, as 
opposed to reporting it directly to a clinician. To get a more detailed understanding 
of this, further research will be required. 
Further, the systematic review highlights the difficulty in effectively 
assessing insulin misuse, while the empirical paper provides an insight into 
information that can be gathered through an effective measure of insulin misuse. 
However, psychometric properties of this measure are still in development, which 
limits its current scope. Both studies highlight the need for the development of tools 
for the assessment of eating disorder psychopathology in men. Current measures are 
failing to capture male concerns adequately, as they tend to emphasise a desire for 
thinness over muscularity. A lack of such a measure makes it more challenging to 
assess the relationship between insulin misuse and weight or shape concerns in men.   
 A striking finding was the differences in reported rates of insulin misuse 
amongst those with a current or historical diagnosis of an eating disorder, compared 
to those with no reported history of an eating disorder. Insulin misuse for the 
purposes of weight loss or control was reported across the spectrum of eating 
disorder categories. This suggests two possibilities: 1. That people with type 1 
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diabetes develop an eating disorder and may misuse insulin as a means to achieve 
their weight goals, or 2. That insulin misuse is not simply a symptom of an eating 
disorder but may be part of a discrete eating disorder experienced by people with 
type 1 diabetes that is currently under-recognised by healthcare professionals. 
Further exploration of this in future research may be beneficial.  
A landmark study by Jones et al. (2000) found that binge eating occurred 
significantly more frequently in participants with diabetes compared to controls, but 
the control group engaged in significantly higher rates of dieting for weight loss. At 
the same time, significantly higher numbers of participants with diabetes met criteria 
for both threshold (2.4 times more likely) and subthreshold eating disorders (1.9 
times more likely) compared to non-diabetic controls. The majority of those with 
diabetes were classified as having an Eating Disorder Not Otherwise Specified 
(EDNOS). For the group with diabetes, insulin omission was the most common form 
of weight loss behaviour reported. Taken together, these results suggest that people 
with type 1 diabetes are more likely to binge eat and to restrict insulin to lose weight, 
as opposed to dieting, which is preferred by a non-diabetic population.  
Berger et al. (2019) found that those with type 1 diabetes and eating 
disorders were also likely to take too much insulin in order to facilitate uncontrolled 
and binge eating. This may link with the cognitive model of bulimia nervosa 
(Cooper, Wells & Todd, 2004) which suggests that the activation of a negative belief 
about the self leads to a cascade of negative automatic thoughts about acceptance by 
oneself or others with associated emotions of guilt, depression or anxiety. This may 
lead to a desire to ‘comfort eat’. In bulimia, this causes a conflict due to both 
positive and negative beliefs held about eating. In diabetes, a similar conflict may 
emerge between the desire to eat and the awareness of the implications of over-
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eating on diabetes. Cooper et al. (2004) suggest that this leads to the emergence of 
“permissive thoughts”, which either provide permission to eat or absolve feelings of 
personal responsibility. This leads to binge eating and the development of a vicious 
cycle, as negative self-appraisals will likely follow a binge.  
The results of the current study confirm that insulin misuse for the purposes 
of weight loss or control occurs in both males and females, and that it occurs in an 
adult population. This is significant as previous research has tended to focus on 
adolescent females, excluding males and adults with type 1 diabetes (e.g. Affenito et 
al., 1997; Colton et al., 2004; Peveler et al., 2005; Rydall et al., 1997). Increased 
recognition and understanding of this behaviour across the spectrum of people with 
type 1 diabetes may lead to earlier identification and improved outcomes.   
These findings may lend support to the hypothesis that, for people with type 
1 diabetes, the presence of insulin misuse for weight loss or control may be best 
understood not as OSFED, as it is commonly categorised, but possibly as a separate 
category such as diabulimia. However, the term diabulimia is controversial and is 
not commonly used by healthcare professionals for this reason. One argument is that 
it only represents bulimic symptomology and does not address other types of 
disturbed eating behaviours in people with diabetes (Colton, Rodin, Bergenstal & 
Parkin, 2009; de Paoli & Rogers, 2018). Another argument is it implies a distinction 
between eating disorders amongst those with diabetes and those without (Colton et 
al., 2009). As insulin misuse is only available to people with diabetes, it could be 
argued that a distinction already exists between eating disorders amongst those with 
diabetes and those without, and this distinction is characterised by insulin misuse. 
Colton et al. (2009) proposed that the preferred nomenclature should be Eating 
Disorder – Diabetes Mellitus Type 1 (ED-DMT1).  
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Individuals with diabetes have reported rejection of the term diabulimia by 
professionals in healthcare settings as being “made up on the internet” (Allan, 2015). 
Despite this, the term appears to have been adopted by the diabetes community and 
is a preferred term to refer to the behaviour of insulin misuse for weight control or 
loss (Allan, 2015). It is beyond the scope of this study to suggest what the preferred 
term should be, but the views and experiences of individuals with type 1 diabetes 
should be considered when identifying preferred nomenclature. The lack of a clear 
diagnostic term poses difficulties for healthcare professionals, who have reported a 
lack of clarity about what constitutes “problematic” behaviour, combined with an 
lack of knowledge about the availability of specialist support services, which can 
cause a sense of anxiety in a healthcare professional when faced with a type 1 
diabetes patient who reports disturbed eating and/or insulin misuse (Tierney, Deaton 
& Whitehead, 2009).  
Group treatment programmes for eating disorder have been found to 
contribute to the development of normative changes to group identity, which can 
lead to improved outcomes (Cruwys, Haslam, Fox & McMahon, 2015), but someone 
with diabulimia may struggle to identify with the group, given the unique nature of 
their difficulties, and this may hinder their recovery (Hastings, McNamara, Allan & 
Marriott, 2016). On this basis, it has been suggested that treatment for insulin misuse 
and disordered eating behaviours for people with type 1 diabetes should involve the 
development of a shared recovery identity with similar others that emphasises 
treatment engagement and disclosure of illness (McNamara & Parsons, 2016). Such 
a group membership may be helpful in providing psychological resources that 
promote recovery, when carefully managed (Hastings et al., 2016).  
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6.6 Clinical Implications 
 The results of this study support the previous research that insulin 
misuse, encompassing the omission of insulin doses, underdosing and overdosing of 
insulin, is a relatively widespread behaviour amongst people with type 1 diabetes, 
and it provides further evidence that this occurs across age groups and genders. As 
outlined above, the potential consequences of insulin misuse are serious and 
potentially life-threatening. The results strongly suggest that healthcare professionals 
working with individuals with type 1 diabetes should routinely screen for insulin 
misuse. The results of this study indicate that a large proportion of people with type 
1 diabetes may be reluctant to admit insulin misuse to their diabetes team, meaning 
this behaviour may be shrouded in some secrecy with a reluctance to admit it in a 
face-to-face setting. Clinicians could consider administering a screening 
questionnaire at routine appointments, such as the insulin measure created by Ames 
(2017) and using the results of that measure to guide appropriate interventions.  
 The presence of insulin misuse may be suggestive of further difficulties, 
particularly disordered eating or diabetes-related distress. In the case of disordered 
eating, evidence suggests that psychoeducation may be useful in some regards, but it 
may not positively impact glycaemic control (Olmsted, Rodin, Rydall, Lawson & 
Daneman, 1997).  For clinicians working in eating disorder services, it is important 
to be aware that type 1 diabetes necessitates paying close attention to portion size 
and calorie content of all food consumed, and treatments for eating disorders that 
encourage taking a relaxed approach to eating are unlikely to be beneficial for people 
with type 1 diabetes (Goebel-Fabbri, 2009). Equally, clinicians working in diabetes 
services should be sensitive to the negative feelings that may be associated with 
weight gain as a result of insulin therapy and the links between this and insulin 
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misuse (Goebel-Fabbri, 2009). Furthermore, the results of this current study suggest 
that diabetes-related distress should be screened for, and that the presence of insulin 
misuse may be suggestive of clinical levels of diabetes-related distress.  
Interventions that have been shown to improve levels of self-efficacy may be 
beneficial (e.g. Snoek et al., 2008). In a randomised controlled trial of patients with 
type 2 diabetes, higher regimen-related distress was associated with greater levels of 
medication nonadherence and higher HbA1c levels cross-sectionally, and reductions 
in regimen distress over time resulted in improved medication adherence and HbA1c 
(Hessler et al., 2014). Taking a less rigid approach to diabetes self-management, 
such as being taught skills to integrate diabetes into one’s life through a flexible diet 
with daily insulin adjustment, rather than trying to live a life around diabetes, has 
been shown to improve HbA1c levels, reduce the impact of diabetes on quality of 
life and improve general wellbeing (DAFNE Study Group, 2002). Less intensive 
approaches to dietary management may also be useful, as strict rules around diets 
have been found to be associated with eating disorder symptomology and higher 
BMIs in a non-clinical sample (Stewart, Williamson & White, 2002). Providing 
further skills to support self-efficacy through a carbohydrate-counting course was 
found to improve quality of life, knowledge of diabetes, coping abilities and HbA1c 
levels in people with type 1 diabetes (Trento et al., 2009).  
Overall, a multidisciplinary care team, including medical management, 
nutritional input and psychological support is considered the best way to support 
individuals with type 1 diabetes with disordered eating and/or insulin misuse, along 
with preventing the development of same (Larrañaga, Docet & García-Mayor, 2011).  
As discussed previously, rates of mental health difficulties appear to be 
higher amongst people with type 1 diabetes than a non-clinical population. The same 
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appears to be true for paediatric populations with a variety of chronic illnesses 
(Chapman, Perry & Strine, 2005; Pinquart & Shen, 2010). The presence of 
depressive disorders, in particular, appears to contribute to more complications in the 
treatment of chronic illness (Chapman et al., 2004). A recent systematic review 
found that children with chronic illnesses that are diet-treated, including but not 
limited to diabetes, are at risk of developing eating disorder psychopathology, and 
that the illness preceded the disordered eating. Again, the diagnosis of a chronic 
illness in childhood may benefit from multi-disciplinary input, particularly 
psychological support, from the point of diagnosis to attempt to mitigate the risk of 
mental health disorders, including disordered eating, developing. 
Finally, the results of this study suggest that insulin misuse is a complex and 
multi-faceted problem. Using a formulation-based approach to understand the 
reasons behind insulin misuse for each individual may underpin the identification of 
appropriate treatment approaches.  
6.7 Future Work 
Despite a broad recruitment strategy, the majority of respondents for the 
empirical study were female (78%). This is in line with findings from similar 
research using an online recruitment strategy (e.g. Ames, 2017; Araia et al., 2017). 
Overall, females have been over-represented in the research regarding insulin misuse 
in type 1 diabetes to date (de Paoli & Rogers, 2017). To balance this, it would be 
useful for future research to focus on the experience of males. Currently, very little is 
known about the reasons that men may misuse insulin, and a useful starting point 
may be to qualitatively investigate this to best inform and guide future quantitative 
studies.  
 129 
Equally, much of the research to date has focused on adolescent populations, 
so further research that focuses on the experiences of adults would be beneficial. 
Recent longitudinal research suggests that the emergence of disordered eating in 
females with type 1 diabetes occurs in adulthood, with over 20% of the sample aged 
over 23 when disordered eating behaviours emerged, and 40% were over 25 when an 
eating disorder emerged (Colton et al., 2015). Focusing on adolescent populations 
risks under-representing an important clinical issue in adult populations. Colton et al. 
(2015) also excluded males, which further emphasises the under-representation of 
males in studies of eating disorder psychopathology and type 1 diabetes. 
The systematic review highlighted the use of custom, unvalidated 
questionnaires by researchers to assess insulin misuse. The insulin measure designed 
by Ames (2017) goes some way towards offering a standardised assessment. Further 
work to validate and generate norms for this measure would be beneficial, as a 
standardised measure would allow for more meaningful comparisons of data in 
future research. However, Ames’ (2017) would also benefit from further refinement, 
including the separation of those who report careful and considered reasons for 
taking their insulin in a manner different to prescribed, such as anticipating low 
blood sugar due to reasons such as sport. This group is currently captured along with 
the broader “insulin misuse” group, which is generally aimed to identify problematic 
reasons for insulin misuse.  
Insulin overdosing as an individual construct was not explored in detail in 
this paper. Preliminary evidence suggests that insulin overdosing may be used to 
facilitate binge eating (Berger et al., 2019), while insulin underdosing or omission 
may be related to weight loss or control (Schober et al., 2011; Snyder et al., 2016). 
 130 
Further research into the reasons for both behaviours would advance the knowledge 
base regarding these behaviours. 
Diabetes-related distress emerged as a key factor in insulin misuse for people 
with type 1 diabetes. Previous research has identified diabetes-related distress as a 
factor in poor glycaemic control and poor self-care for people with diabetes, which 
has not been found for depression (Delahanty et al., 2007; Fisher et al., 2010; 
Hessler et al., 2014). Further research focusing on interventions that reduce diabetes-
related distress may be beneficial for identifying pathways to reduce insulin misuse.  
Finally, this study also provides evidence for there being both ‘proactive’ 
reasons along with more ‘reactive’ reasons for insulin misuse. As such, and in line 
with feedback from people with diabetes, ‘insulin misuse’ as a term may be 
perceived as ‘blaming’ or ‘shaming’, particularly when many people take insulin 
differently than prescribed for planned reasons. Potentially appropriate terms for 
future research could include ‘insulin use not as prescribed (NAP)’ or ‘insulin use 
not as directed (NAD)’. These terms both allow scope for discussion of taking 
insulin differently for both proactive reasons, such as planning ahead to prevent 
hypoglycaemia during exercise, and more reactive occurrences, such as not taking 
insulin due to embarrassment, fear of weight gain or for reasons related to diabetes 
distress. The terms also allow for the expertise of the person living with diabetes, 
without being judgemental or blaming. It would be useful to discuss these terms with 
members of the diabetes community to ensure that they align with lived experiences 
and are not perceived negatively by individuals with diabetes.  
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6.8 Conclusions 
The current research investigated insulin misuse in people with type 1 
diabetes. Insulin misuse occurs in both adult males and females with type 1 diabetes. 
It is associated with diabetes-related distress, and also with eating disorder 
psychopathology and body shape dissatisfaction. It occurs more frequently in women 
than men, and a variety of reasons were provided for the behaviour. Contrary to 
some previous research, men do report insulin misuse for the purposes of weight loss 
or control, but prevalence rates could not be established due to variation in 
methodology. Routine and regular screening for insulin misuse should be considered 
by clinicians working in both diabetes and eating disorders services, as it may be 
suggestive of further difficulties. Those who misuse insulin, particularly in the 
context of disordered eating, may benefit from individual and tailored treatment 
approaches to improve their overall wellbeing and physical health outcomes.  
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Appendix A 
Formatting Guidance for Diabetes Care Journal 
Available from http://care.diabetesjournals.org/content/instructions-for-
authors#Section6  
 
Diabetes Care Instructions for Authors 
Original Articles 
Original Articles should be arranged in the following order: title page, structured 
abstract, introduction (no heading), Research Design and Methods, Results, 
Conclusions, Acknowledgments, References, tables, and figure legends. 
• A structured abstract is required for all Original Articles. Abstracts for an Original 
Article should not exceed 250 words. (This is not to be confused with abstracts 
submitted to the Annual Scientific Meeting, for which the word limit is higher.) The 
abstract must be self-contained and clear without reference to the text and should be 
written for a general journal readership. The abstract format should include four 
sections: Objective (the purpose or hypothesis of study), Research Design and 
Methods (the basic design, setting, number of participants and selection criteria, 
treatment or intervention, and methods of assessment), Results (significant data 
found), and Conclusions (the validity, limitations, and clinical applicability of the 
study and its results). 
• The Conclusions section should discuss the findings of the study in the context of 
past research concerning the topic of the article, in particular highlighting how these 
findings add new information. Also, this section should, where possible, assess the 
possible clinical relevance of the findings avoiding any claim or terminology of 
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superiority, especially when statistically significant but quantitatively modest 
differences are found. 
• The word count limit for Original Articles is 4,000 words, excluding words in 
tables, table legends, figure legends, title page, acknowledgments, and references.  
• The article should contain no more than 40 references and the reference section 
should be single spaced with justified margins. 
• The article should contain no more than a combination of 4 tables and/or figures. 
• A conflict-of-interest statement for all authors must be included in the 
Acknowledgments section of the main document, which should follow the main text 
and precede the references. If there are no relevant conflicts of interest to disclose, 
authors should indicate as such in the Acknowledgments section. 
• In the case of multicenter studies, authors should provide a list of participating 
investigators in an appendix to the paper. Papers will not be reviewed if this 
information is not included. 
• Where appropriate, clinical and epidemiological studies should be analyzed to see 
if there is an effect of sex or ethnicity. If there is no effect, it should be stated as such 
in the Results section. 
• Randomized Clinical Trial Reporting. Authors of reports on randomized 
controlled trials are required to use the instructions and checklist in the Consolidated 
Standards of Reporting Trials (CONSORT) Statement. The instructions and 
checklist are designed to ensure that information pertinent to the trial is included in 
the study report. CONSORT information may be included in a supplemental material 
online-only file so that it does not affect word count limitations. 
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• All clinical trials submitted to Diabetes Care for consideration of publication must 
be registered with a clinical trial registry approved by the International Committee of 
Medical Journal Editors (ICMJE). Please see Clinical Trials for more information. 
 
 
Diabetes Care Guidelines for Systematic Reviews and Meta-Analyses  
Systematic reviews and meta-analyses are systematic, critical assessments of 
literature and data sources pertaining to clinical topics that emphasize factors such as 
cause, diagnosis, prognosis, therapy, or prevention. Meta-analyses that address 
questions for which there is clinical equipoise are preferred.  
All articles or data sources should be searched for and selected systematically for 
inclusion and critically evaluated, and the search and selection process should be 
described in the manuscript. The specific type of study or analysis, population, 
intervention, exposure, and tests or outcomes should be described for each article or 
data source (PICOS format). The data sources should be as current as possible, 
ideally with the search having been conducted within several months of manuscript 
submission.  
For meta-analyses of randomized controlled trials, follow PRISMA reporting 
guidelines and checklist. For meta-analyses of observational studies in 
epidemiology, follow MOOSE reporting guidelines.  
Meta-analyses and systematic reviews not following these guidelines will not be peer 
reviewed. Additional criteria appear below.  
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Title  
Include either “meta-analysis” or “systematic review,” as appropriate, in a subtitle 
following the title.  
Abstract 
Word limit: 250 words  
Structure with the following headings: Background, Purpose, Data Sources, Study 
Selection, Data Extraction, Data Synthesis, Limitations, Conclusions.  
Manuscript 
Word limit: 5,000 words (excluding abstract and references)  
Please format with the following sections: Introduction, Methods, Results, and 
Discussion. 
End the Introduction section with a clear statement of the study’s objectives or 
hypotheses.  
The Methods section should include the following subheadings: • Data Sources and 
Searches  
• Study Selection 
• Data Extraction and Quality Assessment • Data Synthesis and Analysis  
For studies that have numerical data and use statistical inference, include a section 
under Methods that describes the methods and specific statistical software used for 
the statistical analyses.  
References: minimum 40, maximum 60 citations  
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Tables and figures: Any combination of 4 tables and/or figures will be accepted—
Include a flow diagram that depicts search and selection processes, along with 
evidence tables.  
MANUSCRIPT FORMAT AND STYLE 
Articles must be in clear and understandable English. Nonnative English authors are 
encouraged to seek the assistance of an English- proficient colleague, or a 
communications agency, such as American Journal Experts, to help improve the 
clarity and readability of a paper before it is submitted to the journal. 
For specific information on the parameters and limits for various manuscript 
categories (e.g., section headings, word limits, etc.), see Manuscript Categories. 
Title Page 
All submissions, regardless of article type, require a title page. The title page should 
include the following: full title; a short running title (less than 47 characters and 
spaces combined); the first name, middle initial, last name, and highest academic 
degree of each author; each author's affiliation (in English) during the time the study 
was conducted; contact information of the corresponding author (name, current 
address, telephone number, fax number, and email address); and the word count and 
number of tables and figures. 
If two authors have equal authorship, it may be noted by * under the author list. 
Main Document 
The main document file includes the title page, abstract, main text, 
acknowledgements, references, tables, and figure legends, in that order. Please do 
not use headers, footers, or endnotes in your paper. 
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The Main Document should be in Word document format (not as a PDF). This will 
allow our Editorial Office to verify word count and our production staff to convert 
your paper (if accepted) into an article. 
Text Composition 
Articles should be written in clear, concise English following the recommendations 
for scientific writing found in Scientific Style and Format, the Council of Science 
Editors (CSE) style manual (7th ed., 2006, Reston, VA, Council of Science Editors). 
All accepted manuscripts will be edited according to the CSE style manual and The 
Chicago Manual of Style  (16th ed., 2010, Chicago, IL, The University of Chicago 
Press) by ADA professional publications staff. The authors are responsible for all 
statements made in their articles or editorials, including any editing changes made by 
staff. Proof pages will be sent to the corresponding author and should be read 
carefully. 
The designations type 1 diabetes and type 2 diabetes should be used when referring 
to the two major forms of diabetes. Abbreviations for diabetes, such as T2D for type 
2 diabetes, should not be used. The term diabetic should not be used as a noun. 
All manuscripts should be double-spaced, in Arial or Times New Roman 12-point 
font, and saved as a .doc, .txt, or .rtf file. In addition, please do not lock or page 
protect your document, and avoid using footnote and endnote functions. 
Abbreviations and Units 
Abbreviations should be used only when necessary, e.g., for long chemical names 
(HEPES), procedures (ELISA), or terms used throughout the article. See the list of 
abbreviations that need not be defined; all others must be defined at first use. 
Abbreviate units of measure only when used with numbers. Abbreviations may be 
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used in tables and figures. The American Medical Association style manual contains 
lists of standard scientific abbreviations. 
Clinical laboratory values and units should be in Système International (SI) form. 
Kilocalories should be used rather than kilojoules.  
HbA1c values should be dually reported as “% (mmol/mol).” Please use the NGSP’s 
HbA1c converter at http://www.ngsp.org/convert1.asp to calculate HbA1c values as 
both % and mmol/mol. 
Font and Margins 
Text, including title and author names, should be in 12-point Arial or Times New 
Roman. Please avoid using boldface font. Text in tables should be no smaller than 
10-point font. Margins should be 1' at the top and bottom and 1" on the left and right 
sides. 
Acknowledgments 
The acknowledgments are located after the main text and before the reference list. 
Acknowledgments should contain the author contributions paragraph, brief 
statements of assistance, the guarantor's name (person[s] taking responsibility for the 
contents of the article), funding/financial support, conflict of interest statement, and 
reference to prior publication of the study in abstract form, where applicable. 
References 
Please place the reference list after the main text and acknowledgments (if 
applicable). Original Articles are limited to 40 references. Letters are allowed 5 
references. Review articles are allowed 60 references, and meta-analyses should 
have no more than 40 references. 
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Reference numbers in the text should appear in chronological order in normal type 
and in parentheses [e.g., "In the study by Norton et al. (23)..."]. Please do not use the 
footnote or endnote function to cite studies or create a reference list. A reference 
manager must have the ability to customize the display of references. For example, 
the reference application should have the option to list the references at the end of 
the paper, as opposed to listing the references as endnotes or footnotes at the bottom 
of each page, and should not embed the list in the text as a series of 
endnotes/footnotes. When using a reference manager (e.g., Thomson's EndNote 
Reference Program), don't forget to generate the list as a bibliography in a style 
suitable to Diabetes Care, and then save and submit as the final step to creating the 
references. Otherwise, references should be manually inserted. 
All authors must be listed by first initials and last name in each reference, and please 
provide inclusive page numbers. Journal titles should be abbreviated according to the 
National Library of Medicine's List of Journals Indexed for Medline; for unlisted 
journals, please provide complete journal titles. Material in press may be cited, but 
copies of such material may be requested. Authors are responsible for the accuracy 
of the references. Click here for examples of how references should be formatted. 
Supplemental Material 
Nonessential tables, figures, and/or videos may accompany articles as online-only 
supplemental material files, but authors are asked to include a comment to the editor 
at the time of manuscript submission that explains the rationale and justification for 
submitting and possibly posting the supplemental information. 
All online-only supplemenal material files should be combined in one document file 
whenever possible and uploaded during the submission process. The file must be 
clearly labeled as "Online-Only Supplemental Material." In addition, supplemental 
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material online-only files must be referenced in the main text of the manuscript at 
least once (e.g., Supplemental Table S1). 
All online-only supplemental material files are subject to peer review but will not be 
composed, copyedited, or proofread by production staff. As such, authors are 
encouraged to review supplemental material files carefully before submission. 
Lists that include names of principal investigators or writing groups may appear 
in print or as online-only supplemental material. Lists of names exceeding 150 words 
should be submitted as online-only supplemental material. Names of principal 
investigators or writing groups should otherwise be included in an in-text appendix, 
located at the end of the main document before the references. 
Supplemental material containing very large datasets should be cited in the text with 
a URL to the material hosted on an author-affiliated website or data repository or 
may appear with a note that the data is available upon request to the author. 
Tables 
Each table should be inserted on a separate page at the end of the document with the 
table number, title, and legend indicated. Table legends should be inserted below the 
table and should not be included inside the table. Tables should be created using 
Word and the "Insert Table" command. Please use Arial or Times New Roman font, 
no smaller than 10 point. Tables with internal divisions are not allowed (i.e., Tables 
1A and B) and should be submitted as individual tables (Tables 1 and 2). Please 
avoid using shading within a table. If a table includes data that require explanation in 
the legend, apply the following sequence of symbols, from top to bottom, left to 
right: *, †, ‡, §, ||, ¶, #, **, ††, ‡‡. 
Figures 
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Diabetes Care uses digital publishing methods throughout the production process. If 
your article is accepted, it will be published in both the print and online journal. The 
following sections provide information on how to format your figures to ensure the 
best possible reproduction of your images. 
Size. Figures should be produced at the size they are to appear in the printed journal. 
Please make sure your figures will fit in one, two, or three columns in width. 
Multipaneled figures should be assembled in a layout that leaves the least amount of 
blank space. 
• 1 column = 13 picas wide, 2.2 in, 5.6 cm 
• 2 columns = 28 picas wide, 4.6 in, 11.7 cm 
• 3 columns = 41 picas, 6.8 in, 17.3 cm 
Font. At 100% size, fonts should be 8–10 points and used consistently throughout 
all figures. 
Text. Information on the axes should be succinct, using abbreviations where 
possible, and the label on the y-axis should read vertically, not horizontally. Key 
information should be placed in any available white space within the figure; if space 
is not available, the information should be placed in the legend. In general, figures 
with multiple parts should be marked A, B, C, etc., with a description of each panel 
included in the legend rather than on the figure. 
Line and bar graphs. Lines in graphs should be bold enough to be easily read after 
reduction, as should all symbols used in the figure. Data points are best marked with 
the following symbols, again assuring that they will be readily distinguishable after 
reduction: . In the figure legend, please use words rather 
than the symbols; e.g., "black circles = group 1; white squares = group 2; black bars 
= blood glucose; white bars = C-peptide." Bars should be black or white only, unless 
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more than two datasets are being presented; additional bars should be drawn with 
clear bold hatch marks or stripes, not shades of gray. 
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Appendix B 
Ethical Approval – granted following submission of required amendments 
 
Faculty of Medicine and Health Sciences Research Ethics Committee 
 
 
 
 
Dear Victoria, 
 
Title: Exploring the relationship between insulin misuse and eating disorder psychopathology in 
adults with type 1 diabetes 
Reference:  2017/18 - 36 
 
Thank you for your e-mail notifying us of the amendments you would like to make to your above proposal. 
These have been considered and we can now confirm that your amendments have been approved.  
 
Please can you ensure that any further amendments to either the protocol or documents submitted are 
notified to us in advance, and also that any adverse events which occur during your project are reported to 
the Committee.  
 
Please can you also arrange to send us a report once your project is completed. 
 
 
Yours sincerely, 
 
 
 
 
 
Professor M J Wilkinson 
Chair  
FMH Research Ethics Committee 
 
 
 
Victoria Matthews 
MED 
 
 
 
 
  
 
16.1.18 
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Appendix C 
Ethical Approval granted for minor amendment 
 
Faculty of Medicine and Health Sciences Research Ethics Committee 
 
 
 
 
Dear Victoria, 
 
Title: Exploring the relationship between insulin misuse and eating disorder psychopathology in 
adults with type 1 diabetes 
Reference:  2017/18 - 36 
 
Thank you for your e-mail notifying us of the amendments you would like to make to your above proposal. 
These have been considered and we can now confirm that your amendments have been approved.  
 
Please can you ensure that any further amendments to either the protocol or documents submitted are 
notified to us in advance, and also that any adverse events which occur during your project are reported to 
the Committee.  
 
Please can you also arrange to send us a report once your project is completed. 
 
 
Yours sincerely, 
 
 
 
 
 
Professor M J Wilkinson 
Chair  
FMH Research Ethics Committee 
 
 
 
Victoria Matthews 
MED 
 
 
 
 
  
 
6.3.18 
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Appendix D 
Participant Information Sheet 
Exploring the relationship between insulin use and eating attitudes and behaviour in 
adults with type 1 diabetes. 
Researcher: Victoria Matthews (Trainee Clinical Psychologist) 
Supervised by: Professor Sian Coker 
Secondary Supervisor: Dr Bonnie Teague 
Doctoral Programme in Clinical Psychology, 
School of Medicine and Health Sciences, 
University of East Anglia 
 
                                    Invitation and Brief Summary 
We would like to invite you to take part in our research study, conducted at the 
University of East Anglia. Taking part in this study is entirely optional, and deciding 
not to participate will not affect you in any way. The study has been approved by the 
Faculty of Medicine and Health Sciences Ethics Committee at UEA (Final approval 
granted 16/01/18; Ref: 2017/18 - 36). 
Before you decide, we would like to give you some information about the study, 
including why the research is being done, and what your involvement would be. You 
can then decide if you are interested in taking part. If you would like more time to 
think about it, you can close this window and return at a later date. Also, you can 
email us with any further questions that you might have about the study. 
                                What is the study about? 
 167 
We are interested in gathering information about what things might make following 
an insulin regime exactly as prescribed more difficult for people with type 1 
diabetes. We are particularly interested in whether there is a relationship between not 
taking insulin as prescribed, and your eating attitudes and behaviours, how you feel 
about your body, your gender, and any distress experienced as a result of having and 
managing diabetes. The aim of the study is to try and understand whether any of 
these things might make managing your insulin regime more difficult. This research 
is being carried out as part of a Doctoral thesis in Clinical Psychology at the 
University of East Anglia (UEA). We hope that this kind of research can deepen our 
understanding and help us to better support people with type 1 diabetes. 
                        Why have I been asked to take part? 
We are interested in recruiting adults aged 18 and over, who have been using insulin 
to manage their type 1 diabetes for at least 12 months. The study is open to anyone 
who lives in the United Kingdom. The focus of this study is on Adults with type 1 
diabetes so we are not seeking to include adults with type 2 diabetes at this time. If 
you have type 2 diabetes we suggest that you exit the information sheet and thank 
you for your interest so far.  
                            What would taking part involve? 
This research will involve participants accessing online study questionnaires. You 
can do this on a phone, computer or tablet and complete it at your own pace. If you 
decide to take part, it may take you up to 45 minutes to minutes to complete the 
questionnaires. You can pause and exit the survey at any time by clicking the “Finish 
later” link. A link to finish the survey will be provided, which you can bookmark or 
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have emailed to yourself. Your answers will not be submitted until you finish the 
survey. 
You will be asked some information about yourself, your insulin management, your 
eating attitudes and behaviours, your feelings about your body shape, and about any 
distress you experience that is related to your diabetes. Most of the questions involve 
selecting the response that you feel best fits your experience, and a small number of 
questions will have space for you to write in extra information if you’d like to. 
There are no right or wrong answers. At the end of completing the questionnaires, 
you will have the option of providing an email address if you would like to be sent a 
summary of the study results on study completion. You can also provide your email 
should you wish to be entered into a prize draw as a thank you for your time 
completing the questionnaires. 
                     What will happen to the information I provide? 
You won’t be asked to provide any information that could personally identify you 
(e.g. your name or date or birth).  All of the information gathered will be stored on 
an encrypted memory stick that can only be accessed by the researchers. It will be 
stored as required by the Data Protection Act (1998) and UEA Policy, and all data 
will be destroyed after 10 years. We will not ask for any contact information, and 
your G.P. or any other healthcare professionals will not be informed that you are 
taking part; nor does the researcher have the ability to identify or contact them. 
There will be an opportunity to provide an email address for the chance to win a £25 
amazon.co.uk gift card at the end of the study, chosen through a random lottery once 
the data collection phase is completed. Likewise, should participants wish to receive 
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a summary of the study findings, we will ask that they provide an email address for 
us to send these. Your email address, if you choose to provide one, will be collected 
and stored entirely separately from your responses to the questionnaires, and it will 
not be possible for anyone – including the researchers - to link your email address 
with your responses. 
As above, your participation in the research is entirely voluntary and you may 
withdraw from the study at any point without giving a reason. However, as no 
individual’s responses can be identified, once you have submitted your responses, it 
will not be possible for your responses to be later removed from the dataset. 
      What are the possible benefits and disadvantages of taking part? 
There are no direct benefits to you to taking part in this research. We hope that your 
responses will help to guide a deeper understanding of some of the issues that people 
with diabetes experience, and may contribute to better support and treatment services 
being developed in the future. 
Completing the questionnaires has the potential to provoke an emotional response, as 
some of the questions may relate to a delicate subject matter for you that trigger 
unpleasant thoughts or memories. The questionnaires are not intended to cause 
distress, but in the event that this occurs, you are reminded that you have the option 
of discontinuing the study at any at any point by clicking “Exit this survey” on any 
page, or you may wish to pause and re-visit the questionnaires at another time. At the 
point you finish or exit the study, an information sheet is provided that includes 
guidance on where to seek support from a variety of organisations, should you feel 
like you wish to do so. 
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                               What if I want to get in touch? 
If you have a question or concern about any aspect of this study, you can email the 
researchers who will do their best to answer your questions. Their details are 
below.  If you remain unhappy and wish to complain formally, you can do this 
through Professor Kenneth Laidlaw (Head of Department and Programme of the 
Doctorate in Clinical Psychology). Contact details are provided below  
                     What will happen to the results of this study? 
The results of this study will be written up and submitted as part of a Doctoral thesis 
in clinical psychology. The results may also be published in research journals and/or 
presented as academic conferences. All data reported, including any quotes used, 
will not allow personal identification of participants involved in the research. Your 
anonymous responses may be shared with future Clinical Psychology trainees 
working within the same research team for the purposes of future researchers. 
                                   Will this impact my future care? 
Your future care will not be impacted at all by taking part in this study. Unless you 
tell them, no healthcare professionals will even be aware of your participation in this 
study. 
              Who is organising, funding and reviewing this study? 
This study is organised and funded by the Doctoral programme in Clinical 
Psychology at the University of East Anglia. The study has been reviewed and 
approved by the Faculty of Medicine and Health Sciences Ethics Committee at UEA 
(Final approval granted 16/01/18; Ref: 2017/18 - 36). 
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                      Further information and contact details 
If you have any questions or comments about the study, please first contact me 
directly using the contact details provided below. Alternatively, you may contact my 
research supervisors, Professor Sian Coker and Dr Bonnie Teague (see below for 
contact information). If you wish to make a complaint you can contact someone 
independent to the study, Professor Kenneth Laidlaw, Head of Department and 
Programme of the Doctorate in Clinical Psychology. Contact details are provided 
below  
If you would like to retain this information pack and contact details for future 
reference, then please print this page or copy the relevant details into a file on your 
device. It will not be possible to return to this page once you begin the survey.   
Contact Details: 
Victoria Matthews 
Doctoral Programme in Clinical Psychology, 
Department of Clinical Psychology 
Norwich Medical School 
University of East Anglia 
Norwich Research Park 
NORWICH, NR4 7TJ 
v.matthews@uea.ac.uk 
 
Professor Sian Coker 
Doctoral Programme in Clinical Psychology, 
Department of Clinical Psychology 
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Norwich Medical School 
University of East Anglia 
Norwich Research Park 
NORWICH, NR4 7TJ 
s.coker@uea.ac.uk 
 
Dr. Bonnie Teague 
Doctoral Programme in Clinical Psychology, 
Department of Clinical Psychology 
Norwich Medical School 
University of East Anglia 
Norwich Research Park 
NORWICH, NR4 7TJ 
b.teague@uea.ac.uk 
  
  
 
Participant Information Sheet Version 4, 5th February 2018 
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Appendix E 
Consent Form 
Exploring the relationship between insulin use and eating attitudes and behaviour in 
adults with type 1 diabetes. 
Researcher: Victoria Matthews (Trainee Clinical Psychologist) 
Supervised by: Professor Sian Coker 
Secondary Supervisor: Dr Bonnie Teague 
Doctoral Programme in Clinical Psychology, 
School of Medicine and Health Sciences, 
University of East Anglia 
 
If you do not agree with any of the following items, please feel free to exit this 
survey. You may return at a later date if you wish, and you may also contact the 
researcher to discuss any concerns that you may have by emailing 
v.matthews@uea.ac.uk 
 
I confirm that I have read the participant information sheet for the above study on the 
previous page. I have had the opportunity to consider the information, ask questions 
and have had these answered satisfactorily.       I agree 
I understand that my participation is voluntary and that I am free to withdraw at any 
time without giving any reason, without my medical care or legal rights being 
affected.           I agree 
I understand that the information collected about me will be used to support other 
research in the future and may be shared anonymously with other researchers who 
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are carrying out related research, such as future Clinical Psychology trainees 
working within this research team at the University of East Anglia.     I agree 
I agree to take part in the above study.         I agree 
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Appendix F 
Debrief 
 
Thank you for taking part in this survey! 
Your responses will go towards deepening our understanding of some of the issues 
that people living with type 1 diabetes experience on a regular basis. On behalf of 
myself and my fellow researchers, we really appreciate you taking the time to 
provide your perspective. 
If you have experienced any distress as a result of any of the questions asked in this 
study, the following organisations may be able to provide support and/or guidance. 
We encourage you to reach out to these organisations if you do feel any distress. 
If you would like to retain this information pack and contact details for future 
reference, then please print this page or copy the relevant details into a file on your 
device. 
NHS Choices: Living with type 1 diabetes 
Information and advice about living with type 1 diabetes 
http://www.nhs.uk/Conditions/Diabetes-type1/Pages/living-with.aspx 
Diabetes UK 
Online information: https://www.diabetes.org.uk/ 
Local in-person support groups for people living with type 1 diabetes: 
https://www.diabetes.org.uk/In_Your_Area/ 
Diabetes UK Online Communities: 
https://www.diabetes.org.uk/How_we_help/Community/Online-communities 
Diabetes UK also offer a counselling service: 
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Diabetes UK Helpline on 0345 123 2399 (Monday to Friday, 9am to 7pm) 
helpline@diabetes.org.uk. 
diabetes.co.uk 
Diabetes.co.uk is a community of people with diabetes, family members, friends, 
supporters and carers, offering their own support and first-hand knowledge. 
B-eat 
Beat is the UK’s eating disorder charity. They have a number of different support 
options available. 
https://www.b-eat.co.uk/support-services 
Diabetics with Eating Disorders (DWED) 
DWED advocates for and represents those suffering from type 1 diabetes and eating 
disorders in the United Kingdom 
http://dwed.org.uk/online-support 
 
If you would like to contact the researcher to discuss any aspect of the study, please 
email v.matthews@uea.ac.uk. Please note that if you contact the research team you 
will no longer remain anonymous; however, any contact will remain confidential. 
 
If you are experiencing significant distress, we would advise you to contact your GP. 
 
If you would like to be emailed a brief summary of results when they are ready, 
please click here to provide an email address: 
https://uea.onlinesurveys.ac.uk/research-findings 
If you would like to be entered into a prize draw for a chance to win a £25 
Amazon.co.uk gift card, please click here: https://uea.onlinesurveys.ac.uk/prize-draw 
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Appendix G 
Insulin Questionnaire 
Living with diabetes is hard work, practically, physically and psychologically. 
Research tells us that many people miss insulin doses sometimes. This questionnaire 
helps us understand why.  
1. What insulin regime are you on?  
a. Long-acting 
b. Short-acting 
c. Both 
2. Do you ever skip (miss out) insulin doses that you know you should take?  
a. Yes 
b. No 
3. In the last 7 days, was this:  
a. Once 
b. 2 – 4 times 
c. 5 – 6 times 
d. 7 or more times 
4. Were these at the same time of day?  
 
5. How would you best describe the reason you missed an insulin dose you 
knew you should take (you may select more than one option)?  
a) Other things took priority at the time (e.g. travelling, work, parenting, 
lack of time, etc) 
b) Negative feelings around diabetes (e.g. frustration, resentment, a sense of 
hopelessness, loss of control, etc) 
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c) As a method of weight control (i.e. to avoid gaining weight) 
d) As a method of weight loss 
e) Avoidance or fear of physical effects (e.g. hypoglycaemia, pain around 
injection, etc) 
f) Anticipating low blood sugar and planning around this 
g) Other 
6. Do you ever take less or more insulin than you know you should?  
a) No 
b) Yes – more 
c) Yes – less 
d) Yes – both 
7. In the last 7 days, was this:  
a) Once 
b) 2 – 4 times 
c) 5 – 6 times 
d) 7 or more times 
Were these at the same time of day?  
 
8. How would you best describe the reason you took more or less insulin than 
you knew you should take? (you may select more than one option)  
a) Other things took priority at the time (e.g. travelling, work, parenting, 
lack of time, etc) 
b) Negative feelings around diabetes (e.g. frustration, resentment, a sense of 
hopelessness, loss of control, etc) 
c) As a method of weight control (i.e. to avoid gaining weight) 
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d) As a method of weight loss 
e) Avoidance or fear of physical effects (e.g. hypoglycaemia, pain around 
injection, etc) 
f) Anticipating low blood sugar and planning around this 
g) Other 
For the following questions, please answer "Yes" or "No". Where your answer is 
"Yes", please elaborate where possible.  
9. Is there a time of day where you would be likely to skip an insulin dose?  
10. Is there a particular dose of insulin that you are likely to skip?  
11. Do you feel that skipping doses, or taking more or less insulin than you 
should, is a problem for you?  
a) Yes 
b) No 
12. Does your mood affect how you take insulin?  
13. Does taking insulin affect your mood?  
14. What makes you less likely to take insulin as you should?  
15. What makes you more likely to take insulin as you should?  
16. What would motivate you to take insulin as you should?  
17. Would you, or do you, tell your diabetes team if you are missing doses?  
a) Yes 
b) No 
c) Not applicable (I do not miss doses) 
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Appendix H 
Eating Disorders Examination Questionnaire 
 
 
 
 1 
ID:                                                                                                           Date: 
 
EATING QUESTIONNAIRE 
 
Instructions: The following questions are concerned with the past four weeks (28 days) 
only. Please read each question carefully. Please answer all of the questions.  Please only 
choose one answer for each question. Thank you. 
 
Questions 1 to 12: Please circle the appropriate number on the right. Remember that the questions 
only refer to the past four weeks (28 days) only. 
 
 
 
  
On how many of the past 28 days …… 
 
 
No 
days 
 
1-5 
days 
 
6-12 
days 
 
13-15 
days 
 
16-22 
days 
 
23-27 
days 
 
Every 
day 
1 Have you been deliberately trying to limit the 
amount of food you eat to influence your shape or 
weight (whether or not you have succeeded)? 
 
 
 
0 
 
 
1 
 
 
2 
 
 
3 
 
 
4 
 
 
5 
 
 
6 
2 Have you gone for long periods of time (8 waking 
hours or more) without eating anything at all in 
order to influence your shape or weight? 
 
 
 
0 
 
 
1 
 
 
2 
 
 
3 
 
 
4 
 
 
5 
 
 
6 
3 Have you tried to exclude from your diet any foods 
that you like in order to influence your shape or 
weight (whether or not you have succeeded)? 
 
 
 
0 
 
 
1 
 
 
2 
 
 
3 
 
 
4 
 
 
5 
 
 
6 
4 Have you tried to follow definite rules regarding 
your eating (for example, a calorie limit) in order to 
influence your shape or weight (whether or not you 
have succeeded)? 
 
 
0 
 
 
1 
 
 
2 
 
 
3 
 
 
4 
 
 
5 
 
 
6 
5 Have you had a definite desire to have an empty 
stomach with the aim of influencing your shape or 
weight? 
 
 
 
0 
 
 
1 
 
 
2 
 
 
3 
 
 
4 
 
 
5 
 
 
6 
6 Have you had a definite desire to have a totally flat 
stomach? 
 
 
 
0 
 
 
1 
 
 
2 
 
 
3 
 
 
4 
 
 
5 
 
 
6 
7 Has thinking about food, eating or calories made it 
very difficult to concentrate on things you are 
interested in (for example, working, following a 
conversation, or reading)? 
 
 
0 
 
 
1 
 
 
2 
 
 
3 
 
 
4 
 
 
5 
 
 
6 
8 Has thinking about shape or weight made it very 
difficult to concentrate on things you are interested 
in (for example, working, following a conversation, 
or reading)? 
 
 
0 
 
 
1 
 
 
2 
 
 
3 
 
 
4 
 
 
5 
 
 
6 
9 Have you had a definite fear of losing control over 
eating? 
 
 
 
0 
 
 
1 
 
 
2 
 
 
3 
 
 
4 
 
 
5 
 
 
6 
10 Have you had a definite fear that you might gain 
weight? 
 
 
 
 
0 
 
 
1 
 
 
2 
 
 
3 
 
 
4 
 
 
5 
 
 
6 
11 Have you felt fat? 
 
 
 
0 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
12 Have you had a strong desire to lose weight? 
 
 
 
0 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
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 2 
 
 
Questions 13-18: Please fill in the appropriate number in the boxes on the right. Remember that 
the questions only refer to the past four weeks (28 days). 
 
 
Over the past four weeks (28 days)……. 
 
13 Over the past 28 days, how many times have you eaten what other people 
would regard as an unusually large amount of food (given the circumstances)? 
 
 
 
…………….. 
14 ….On how many of these times did you have a sense of having lost control 
over your eating (at the time that you were eating)? 
 
 
…………….. 
15 Over the past 28 days, on how many DAYS have such episodes of overeating 
occurred (i.e. you have eaten an unusually large amount of food and have had 
a sense of loss of control at the time)? 
 
 
 
 
…………….. 
16 Over the past 28 days, how many times have you made yourself sick (vomit) 
as a means of controlling your shape or weight? 
 
 
…………….. 
17 Over the past 28 days, how many times have you taken laxatives as a means 
of controlling your shape or weight? 
 
 
…………….. 
18 Over the past 28 days, how many times have you exercised in a “driven” or 
“compulsive” way as a means of controlling your weight, shape or amount of 
fat or to burn off calories?  
 
 
 
…………….. 
 
 
Questions 19-21: Please circle the appropriate number. Please note that for these questions the 
term “binge eating” means eating what others would regard as an unusually large amount of food 
for the circumstances, accompanied by a sense of having lost control over eating. 
 
 
 
19 
 
Over the past 28 days, on how many days have 
you eaten in secret (ie, furtively)?......Do not 
count episodes of binge eating 
 
No 
days 
 
1-5 
days 
 
6-12 
days 
 
13-15 
days 
 
16-22 
days 
 
23-27 
days 
 
Every 
day 
 
0 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
 
20 
 
On what proportion of the times that you have 
eaten have you felt guilty (felt that you’ve done 
wrong) because of its effect on your shape or 
weight? 
......Do not count episodes of binge eating 
 
 
None 
of the 
times 
 
 
A few 
of the 
times 
 
Less 
than 
half 
 
Half of 
the 
times 
 
More 
than 
half 
 
 
Most 
of the 
time 
 
Every 
time 
 
0 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
21 
 
Over the past 28 days, how concerned have you 
been about other people seeing you eat? 
......Do not count episodes of binge eating 
 
 
Not at 
all 
 
Slightly 
 
Moderately 
 
Markedly 
 
0 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
  
 
 3 
 
Questions 22-28: Please circle the appropriate number on the right. Remember that the questions 
only refer to the past four weeks (28 days) 
 
 
 
 
 
What is your weight at present? (Please give your best estimate). ……………………………. 
 
 
What is your height? (Please give your best estimate).   ……………………………. 
 
 
If female: Over the past three-to-four months have you missed any menstrual periods? …………… 
 
If so, how many?  ……………………………. 
 
Have you been taking the “pill”? ………………….. 
 
 
THANK YOU 
 
 
 
EDE-Q reproduced with permission.  Fairburn and Beglin (2008).  In Fairburn, C. G. (2008). Cognitive Behavior Therapy and Eating 
Disorders.  Guilford Press, New York. 
 
 
 
  
On how many of the past 28 days …… 
 
 
Not 
at all 
 
Slightly 
 
Moderately  
 
Markedly 
 
22 Has your weight influenced how you think about 
(judge) yourself as a person? 
 
 
 
0 
 
 
1 
 
 
2 
 
 
3 
 
 
4 
 
 
5 
 
 
6 
23 Has your shape influenced how you think about 
(judge) yourself as a person? 
 
 
 
0 
 
 
1 
 
 
2 
 
 
3 
 
 
4 
 
 
5 
 
 
6 
24 How much would it have upset you if you had been 
asked to weigh yourself once a week (no more, or 
less, often) for the next four weeks? 
 
 
 
0 
 
 
1 
 
 
2 
 
 
3 
 
 
4 
 
 
5 
 
 
6 
 
25 
 
How dissatisfied have you been with your weight? 
 
 
 
0 
 
 
1 
 
 
2 
 
 
3 
 
 
4 
 
 
5 
 
 
6 
 
26 
 
How dissatisfied have you been with your shape? 
 
 
 
0 
 
 
1 
 
 
2 
 
 
3 
 
 
4 
 
 
5 
 
 
6 
27 How uncomfortable have you felt seeing your body 
(for example, seeing your shape in the mirror, in a 
shop window reflection, while undressing or taking 
a bath or shower)? 
 
 
 
0 
 
 
1 
 
 
2 
 
 
3 
 
 
4 
 
 
5 
 
 
6 
28 How uncomfortable have you felt about others 
seeing your shape or figure (for example, in 
communal changing rooms, when swimming, or 
wearing tight clothes)? 
 
 
 
0 
 
 
1 
 
 
2 
 
 
3 
 
 
4 
 
 
5 
 
 
6 
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Appendix I 
Body Shape Questionnaire 
Over the past FOUR weeks:  
Please don't select more than 1 answer(s) per row. 
 Never Rarely Sometimes Often 
Very 
often 
Always 
Has feeling bored made you brood 
about your shape? 
      
Have you been so worried about your 
shape that you have been feeling you 
ought to diet? 
      
Have you thought that your thighs, 
hips or bottom are too large for the 
rest of you? 
      
Have you been afraid that you might 
become fat (or fatter)? 
      
Have you worried about your flesh 
being not firm enough? 
      
Has feeling full (e.g. after eating a 
large meal) made you feel fat? 
      
Have you felt so bad about your 
shape that you have cried? 
      
Have you avoided running because 
your flesh might wobble? 
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Has being with thin people made you 
feel self-conscious about your shape? 
      
Have you worried about your thighs 
spreading out when sitting down? 
      
Has eating even a small amount of 
food made you feel fat? 
      
Have you noticed the shape of other 
people and felt that your own shape 
compared unfavourably? 
      
Has thinking about your shape 
interfered with your ability to 
concentrate (e.g. while watching 
television, reading, listening to 
conversations)? 
      
Has being naked, such as when 
taking a bath, made you feel fat? 
      
Have you avoided wearing clothes 
which make you particularly aware 
of the shape of your body? 
      
Have you imagined cutting off fleshy 
areas of your body? 
      
Has eating sweets, cakes, or other 
high calorie food made you feel fat? 
      
Have you not gone out to social 
occasions (e.g. parties) because you 
have felt bad about your shape? 
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Have you felt excessively large and 
rounded? 
      
Have you felt ashamed of your body?       
Has worry about your shape made 
you diet? 
      
Have you felt happiest about your 
shape when your stomach has been 
empty (e.g. in the morning)? 
      
Have you thought that you are in the 
shape you are because you lack self-
control? 
      
Have you worried about other people 
seeing rolls of fat around your waist 
or stomach? 
      
Have you felt that it is not fair that 
other people are thinner than you? 
      
Have you vomited in order to feel 
thinner? 
      
When in company have your worried 
about taking up too much room (e.g. 
sitting on a sofa, or a bus seat)? 
      
Have you worried about your flesh 
being dimply? 
      
Has seeing your reflection (e.g. in a 
mirror or shop window) made you 
feel bad about your shape? 
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Have you pinched areas of your body 
to see how much fat there is? 
      
Have you avoided situations where 
people could see your body (e.g. 
communal changing rooms or 
swimming baths)? 
      
Have you taken laxatives in order to 
feel thinner? 
      
Have you been particularly self-
conscious about your shape when in 
the company of other people? 
      
Has worry about your shape made 
you feel you ought to exercise? 
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Appendix J 
Diabetes Distress Scale 
Living with diabetes can sometimes be tough. There may be many problems and hassles concerning 
diabetes and they can vary greatly in severity. Problems may range from minor hassles to major life 
difficulties. Listed below are 17 potential problem areas that people with diabetes may experience. 
Consider the degree to which each of the 17 items may have distressed or bothered you DURING 
THE PAST MONTH and circle the appropriate answer. 
Please note that we are asking you to indicate the degree to which each item may be bothering you in 
your life, NOT whether the item is merely true for you. If you feel that a particular item is not a 
bother or a problem for you, you would select "Not a problem". If it is very bothersome to you, you 
might select "A very serious problem". 
 
To what degree has the following distressed or bothered you over the past month?  
Please don't select more than 1 answer(s) per row. 
 
Not a 
Problem 
A Slight 
Problem 
A 
Moderate 
Problem 
Somewhat 
Serious 
Problem 
A 
Serious 
Problem 
A Very 
Serious 
Problem 
1. Feeling that diabetes is taking 
up too much of my mental and 
physical energy every day. 
      
2. Feeling that my doctor doesn't 
know enough about diabetes and 
diabetes care. 
      
3. Feeling angry, scared, and/or 
depressed when I think about 
living with diabetes. 
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4. Feeling that my doctor doesn't 
give me clear enough directions 
on how to manage my diabetes. 
      
5. Feeling that I am not testing 
my blood sugars frequently 
enough. 
      
6. Feeling that I am often failing 
with my diabetes routine. 
      
7. Feeling that friends or family 
are not supportive enough of 
self-care efforts (e.g. planning 
activities that conflict with my 
schedule, encouraging me to 
      
eat the "wrong" foods).       
8. Feeling that diabetes controls 
my life. 
      
9. Feeling that my doctor doesn't 
take my concerns seriously 
enough. 
      
10. Not feeling confident in my 
day-to-day ability to manage 
diabetes. 
      
11. Feeling that I will end up 
with serious long-term 
complications, no matter what I 
do. 
      
 189 
12. Feeling that I am not sticking 
closely enough to a good meal 
plan. 
      
13. Feeling that friends or family 
don't appreciate how difficult 
living with diabetes can be. 
      
14. Feeling overwhelmed by the 
demands of living with diabetes. 
      
15. Feeling that I don't have a 
doctor who I can see regularly 
enough about my diabetes. 
      
16. Not feeling motivated to keep 
up my diabetes self management. 
      
17. Feeling that friends or family 
don't give me the emotional 
support that I would like. 
      
 
 
 
